[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZ2zVQqW-UksaszOmvSI640fmeZuHBM4rg7Gzk4KukAY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"University of Nebraska",[4,6],"University of Nebraska Lincoln",513,false,82,11,1094882,54,333,[15,18,21,24,27,29,31,33],{"name":16,"count":17},"Lymphoma",21,{"name":19,"count":20},"Breast Cancer",14,{"name":22,"count":23},"Peripheral Arterial Disease",10,{"name":25,"count":26},"Leukemia",8,{"name":28,"count":26},"Rheumatoid Arthritis",{"name":30,"count":26},"Obesity",{"name":32,"count":26},"Multiple Myeloma",{"name":34,"count":35},"Prostate Cancer",7,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01750073","Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer","2022-05-01","Cyclophosphamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05621096","Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma","2025-01-20","Liso-cel",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05177536","Iberdomide Maintenance Therapy in Patients With Multiple Myeloma","2026-01","Iberdomide",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04748419","Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab","2026-03","Durvalumab 50 MG\u002FML",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05220046","Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers","2026-05","Psilocybin",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT02842424","Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis","2026-06","Ramipril",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06319339","Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease","2026-08","Vumerity",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05069038","Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy","2026-09","Palbociclib 125mg",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT03386500","Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer","2026-10","BMX-001",{"nctId":83,"briefTitle":84,"date":85,"intervention":81},"NCT05254327","Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With\u002FWithout BMX-001","2027-05",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,117,379,409,438,456,474,492,510,528,546,564,582,600,618,636,654,672,704,803,839,861,1055,1112,1157,1264,1309,1365,1391,1430,1451,1469,1487,1505,1523,1548,1573,1591,1609,1635,1653,1683,1701,1730,1748,1769,1790,1813,1843,1883,1901,1927,1950,1978,2000,2038,2064,2100,2134,2159,2177,2195,2221,2239,2264,2290,2321,2339,2357,2375,2398,2416,2442,2460,2486,2509,2536,2554,2572,2590,2613,2639,2663,2689,2712,2737,2755,2781,2806,2824,2854,2878,2902,2920,2946,2964,2990,3008,3026,3044,3062,3087,3105,3168,3234,3300,3361,3402,3436,3466,3496,3533,3563,3593,3619,3653,3679,3705,3750,3782,3804,3826,3848,3870,3892,3914,3948,3970,3992,4014,4036,4058,4085,4123,4161,4183,4220,4238,4256,4274,4292,4310,4328,4351,4379,4397,4415,4433,4451,4476,4494,4512,4530,4555,4573,4597,4622,4640,4658,4676,4699,4717,4743,4761,4785,4803,4821,4839,4864,4882,4907,4932,4950,4968,4994,5019,5045,5070,5088,5106,5124,5142,5160,5178,5196,5214,5232,5250,5268,5286,5304,5322,5340,5358,5376,5394,5412,5430,5448,5471,5495,5513,5531,5549,5567,5596,5620,5638,5660,5685,5709,5727,5751,5769,5793,5817,5835,5861,5885,5912,5930,5955,5973,5998,6016,6034,6052,6076,6103,6121,6139,6164,6182,6207,6231,6257,6275,6293,6311,6352,6383,6409,6442,6472,6507,6529,6551,6574,6599,6621,6643,6671,6689,6707,6725,6750,6768,6795,6813,6837,6861,6884,6906,6928,6954,6972,6995,7021,7049,7074,7092,7110,7128,7151,7169,7193,7219],{"intervention":66,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":115},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":65},[108],{"nctId":63,"briefTitle":64,"status":109,"phases":110,"primaryCompletion":65,"completion":65,"start":111,"enrollment":112,"conditions":113,"interventions":114},"RECRUITING",[91],"2016-02-25",70,[22],[66],{"trials":116,"activeCount":99},[],{"intervention":118,"totalTrials":119,"cells":120},"rituximab",9,{"EARLY_PHASE1":121,"PHASE1":146,"PHASE2":148,"PHASE3":338,"PHASE4":375,"NA":377},{"trials":122,"activeCount":99},[123],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":137},"NCT00736450","Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","TERMINATED",[87],"2012-10-09","2008-07-23",37,[132,133,134,135,136],"Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma",[138,118,139,140,141,142,143,144,145],"oblimersen sodium","cyclophosphamide","doxorubicin hydrochloride","vincristine sulfate","prednisone","microarray analysis","gene expression analysis","cytogenetic analysis",{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[150,161,174,183,205,215],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT00031642","Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation","COMPLETED",[88,89],"2005-11-01","2008-03-01","2002-01-01",26,[16],[118],{"nctId":162,"briefTitle":163,"status":153,"phases":164,"primaryCompletion":155,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT00080886","Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",[89],"2015-03-12","2002-05-08",68,[16],[118,170,171,172,173],"carmustine","cytarabine","etoposide","melphalan",{"nctId":175,"briefTitle":176,"status":153,"phases":177,"primaryCompletion":157,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":182},"NCT00007852","Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",[89],"2011-01-01","2000-09-01",44,[16],[118,170,171,172,173],{"nctId":184,"briefTitle":185,"status":153,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":198},"NCT01035463","Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma",[88,89],"2017-07-27","2018-07-27","2009-11-12",74,[192,193,194,195,196,197],"Anaplastic Large Cell Lymphoma, ALK-Negative","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma",[199,200,201,202,203,204],"Carmustine","Cytarabine","Etoposide","Lenalidomide","Melphalan","Rituximab",{"nctId":206,"briefTitle":207,"status":153,"phases":208,"primaryCompletion":209,"completion":210,"start":179,"conditions":211,"interventions":212},"NCT00007865","Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",[89],"2004-03-01","2008-04-22",[16],[118,213,172,214],"carboplatin","ifosfamide",{"nctId":216,"briefTitle":217,"status":126,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":329},"NCT01044745","Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",[89],"2012-12-19","2017-10-10","2009-12-10",20,[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],"Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Blastic Phase Chronic Myelogenous Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","de Novo Myelodysplastic Syndromes","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Graft Versus Host Disease","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Previously Treated Myelodysplastic Syndromes","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Relapsing Chronic Myelogenous Leukemia","Secondary Myelodysplastic Syndromes","Splenic Marginal Zone Lymphoma","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Chronic Lymphocytic Leukemia","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Mycosis Fungoides\u002FSezary Syndrome","Stage I Small Lymphocytic Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage II Mycosis Fungoides\u002FSezary Syndrome","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Mycosis Fungoides\u002FSezary Syndrome","Stage IV Small Lymphocytic Lymphoma","Untreated Adult Acute Lymphoblastic Leukemia","Untreated Adult Acute Myeloid Leukemia","Waldenström Macroglobulinemia",[118,330,331,332,333,139,334,335,336,337],"mycophenolate mofetil","tacrolimus","anti-thymocyte globulin","graft versus host disease prophylaxis\u002Ftherapy","fludarabine phosphate","busulfan","graft-versus-tumor induction therapy","immunosuppressive therapy",{"trials":339,"activeCount":95,"soonestReadout":354},[340,350],{"nctId":341,"briefTitle":342,"status":153,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"conditions":347,"interventions":348},"NCT00004112","Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",[90],"2000-12-01","2003-03-01","1999-09-01",[16],[118,349,139,140,142,141],"CHOP regimen",{"nctId":351,"briefTitle":352,"status":109,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT03414502","Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response",[90],"2028-03","2029-03","2007-12-10",400,[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],"Methotrexate","Abatacept","Adalimumab","Azathioprine","Baricitinib","Certolizumab","Etanercept","Golimumab","Hydroxychloroquine","Infliximab","Leflunomide","Minocycline","Sarilumab","Sulfasalazine","Tofacitinib",{"trials":376,"activeCount":99},[],{"trials":378,"activeCount":99},[],{"intervention":360,"totalTrials":380,"cells":381},2,{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":405,"NA":407},{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":99},[],{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":95,"soonestReadout":354},[390,394],{"nctId":351,"briefTitle":352,"status":109,"phases":391,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":392,"interventions":393},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"nctId":395,"briefTitle":396,"status":153,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT00579644","Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone",[90],"2006-05-31","2001-03-28",91,[28],[403,404],"Combination of Minocycline and MTX or MTX alone","methotrexate",{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"intervention":370,"totalTrials":380,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":434,"NA":436},{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":99},[],{"trials":418,"activeCount":95,"soonestReadout":354},[419,423],{"nctId":351,"briefTitle":352,"status":109,"phases":420,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":421,"interventions":422},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"nctId":424,"briefTitle":425,"status":153,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":431},"NCT00579878","Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis",[90],"2010-03-11","2001-03-27",69,[28],[370,432,433],"Methotrexate-Sulfasalazine-Hydroxychloroquine","Leflunomide-Sulfasalazine-Hydroxychloroquine",{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"intervention":361,"totalTrials":95,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":452,"NA":454},{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"trials":445,"activeCount":99},[],{"trials":447,"activeCount":95,"soonestReadout":354},[448],{"nctId":351,"briefTitle":352,"status":109,"phases":449,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":450,"interventions":451},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"intervention":362,"totalTrials":95,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":470,"NA":472},{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":95,"soonestReadout":354},[466],{"nctId":351,"briefTitle":352,"status":109,"phases":467,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":468,"interventions":469},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":99},[],{"intervention":363,"totalTrials":95,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":488,"NA":490},{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":95,"soonestReadout":354},[484],{"nctId":351,"briefTitle":352,"status":109,"phases":485,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":486,"interventions":487},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"intervention":364,"totalTrials":95,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":506,"NA":508},{"trials":495,"activeCount":99},[],{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":99},[],{"trials":501,"activeCount":95,"soonestReadout":354},[502],{"nctId":351,"briefTitle":352,"status":109,"phases":503,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":504,"interventions":505},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"intervention":365,"totalTrials":95,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":524,"NA":526},{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":95,"soonestReadout":354},[520],{"nctId":351,"briefTitle":352,"status":109,"phases":521,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":522,"interventions":523},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"intervention":366,"totalTrials":95,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":95,"soonestReadout":354},[538],{"nctId":351,"briefTitle":352,"status":109,"phases":539,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":540,"interventions":541},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":99},[],{"intervention":367,"totalTrials":95,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":560,"NA":562},{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":95,"soonestReadout":354},[556],{"nctId":351,"briefTitle":352,"status":109,"phases":557,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":558,"interventions":559},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":99},[],{"intervention":368,"totalTrials":95,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":578,"NA":580},{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[],{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":95,"soonestReadout":354},[574],{"nctId":351,"briefTitle":352,"status":109,"phases":575,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":576,"interventions":577},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[],{"intervention":369,"totalTrials":95,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":596,"NA":598},{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":95,"soonestReadout":354},[592],{"nctId":351,"briefTitle":352,"status":109,"phases":593,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":594,"interventions":595},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"intervention":371,"totalTrials":95,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"trials":607,"activeCount":99},[],{"trials":609,"activeCount":95,"soonestReadout":354},[610],{"nctId":351,"briefTitle":352,"status":109,"phases":611,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":612,"interventions":613},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":615,"activeCount":99},[],{"trials":617,"activeCount":99},[],{"intervention":372,"totalTrials":95,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":632,"NA":634},{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":95,"soonestReadout":354},[628],{"nctId":351,"briefTitle":352,"status":109,"phases":629,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":630,"interventions":631},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[],{"intervention":373,"totalTrials":95,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":650,"NA":652},{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":95,"soonestReadout":354},[646],{"nctId":351,"briefTitle":352,"status":109,"phases":647,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":648,"interventions":649},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":651,"activeCount":99},[],{"trials":653,"activeCount":99},[],{"intervention":374,"totalTrials":95,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":668,"NA":670},{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":95,"soonestReadout":354},[664],{"nctId":351,"briefTitle":352,"status":109,"phases":665,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":666,"interventions":667},[90],[28],[360,361,362,363,364,365,366,367,368,369,370,371,204,372,373,374],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[],{"intervention":81,"totalTrials":380,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":698,"PHASE4":700,"NA":702},{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":380,"soonestReadout":80},[680,688],{"nctId":83,"briefTitle":84,"status":109,"phases":681,"primaryCompletion":85,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":687},[89],"2029-06","2022-08-15",118,[686],"Rectal Cancer",[81],{"nctId":78,"briefTitle":79,"status":689,"phases":690,"primaryCompletion":80,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":697},"ACTIVE_NOT_RECRUITING",[88,89],"2029-12","2017-11-28",24,[695,696],"Anal Cancer, Squamous Cell Carcinoma","Radiation Exposure",[81],{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"intervention":330,"totalTrials":705,"cells":706},6,{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":783,"PHASE4":785,"NA":801},{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"trials":712,"activeCount":95,"soonestReadout":753},[713,729,749,764,779],{"nctId":714,"briefTitle":715,"status":716,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":720,"interventions":724},"NCT00816413","Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","WITHDRAWN",[88,89],"2010-02","2008-09",[721,25,16,722,723],"Chronic Myeloproliferative Disorders","Myelodysplastic Syndromes","Nonmalignant Neoplasm",[725,330,726,145,727,728],"cyclosporine","pentostatin","fluorescence in situ hybridization","protein analysis",{"nctId":730,"briefTitle":731,"status":153,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":744},"NCT00571662","Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant",[89],"2008-12-30","2000-12-08",76,[737,738,739,740,722,32,741,742,743],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Chronic Lymphocytic Leukemia","Non-Hodgkins Lymphoma","Hodgkins Disease","Peripheral T-cell Lymphoma",[745,746,747,748],"Pentostatin","Cyclosporine A","Mycophenolate Mofetil","G-CSF",{"nctId":750,"briefTitle":751,"status":109,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":760},"NCT06799195","Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",[89],"2031-04","2031-11","2025-06-23",126,[758,759],"Hematological Malignancies","Graft-versus-Host Disease (GVHD)",[761,762,763,747],"Attenuated-dose Cyclophosphamide","High-dose Cyclophosphamide","Sirolimus",{"nctId":765,"briefTitle":766,"status":153,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":776},"NCT00611351","Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer",[89],"2008-02-01","2008-09-17","2005-06-07",5,[242,25,16,773,722,774,775],"Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Diseases","Secondary Myelofibrosis",[332,335,139,330,331,777,778],"polymerase chain reaction","polymorphism analysis",{"nctId":216,"briefTitle":217,"status":126,"phases":780,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":781,"interventions":782},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[787],{"nctId":788,"briefTitle":789,"status":153,"phases":790,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT00556933","Improved Induction and Maintenance Immunosuppression in Kidney Transplantation",[91],"2011-04-01","2011-06-01","2004-04-01",180,[796],"End-stage Renal Disease",[798,330,799,800,331],"rabbit anti-thymocyte globulin - single dose","rabbit anti-thymocyte globulin - 4 doses","sirolimus",{"trials":802,"activeCount":99},[],{"intervention":804,"totalTrials":380,"cells":805},"Escitalopram",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":823,"PHASE4":825,"NA":837},{"trials":807,"activeCount":99},[],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":95,"soonestReadout":816},[812],{"nctId":813,"briefTitle":814,"status":109,"phases":815,"primaryCompletion":816,"completion":682,"start":817,"enrollment":222,"conditions":818,"interventions":821},"NCT03728673","A Study Utilizing Escitalopram in Glioma Patients",[89],"2027-06","2019-03-06",[819,820],"Glioma of Brain","Glioma",[822],"Escitalopram Oral",{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[827],{"nctId":828,"briefTitle":829,"status":153,"phases":830,"primaryCompletion":831,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT00536172","Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment",[91],"2012-06-01","2007-12-01",160,[835],"Depression",[804],{"trials":838,"activeCount":99},[],{"intervention":763,"totalTrials":380,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":851,"PHASE4":853,"NA":859},{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":95,"soonestReadout":753},[847],{"nctId":750,"briefTitle":751,"status":109,"phases":848,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":849,"interventions":850},[89],[758,759],[761,762,763,747],{"trials":852,"activeCount":99},[],{"trials":854,"activeCount":99},[855],{"nctId":788,"briefTitle":789,"status":153,"phases":856,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":857,"interventions":858},[91],[796],[798,330,799,800,331],{"trials":860,"activeCount":99},[],{"intervention":139,"totalTrials":862,"cells":863},15,{"EARLY_PHASE1":864,"PHASE1":870,"PHASE2":872,"PHASE3":1045,"PHASE4":1051,"NA":1053},{"trials":865,"activeCount":99},[866],{"nctId":124,"briefTitle":125,"status":126,"phases":867,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":868,"interventions":869},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":95,"soonestReadout":40},[874,890,907,919,932,936,946,960,972,990,1010,1022,1041],{"nctId":875,"briefTitle":876,"status":153,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":883},"NCT00499083","Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II\u002FIII Breast Cancer (Women)",[89],"2009-07-01","2010-01-28","2006-05-01",17,[19],[884,885,139,140,886,887,144,888,889],"therapeutic autologous dendritic cells","aromatase inhibition therapy","paclitaxel","tamoxifen citrate","protein expression analysis","reverse transcriptase-polymerase chain reaction",{"nctId":891,"briefTitle":892,"status":153,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":222,"conditions":896,"interventions":904},"NCT02654119","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2\u002FNeu Positive Breast Cancer After Surgery",[89],"2025-12-08","2015-12-11",[897,898,899,900,901,902,903],"HER2 Positive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7",[41,905,906],"Paclitaxel","Trastuzumab",{"nctId":908,"briefTitle":909,"status":153,"phases":910,"primaryCompletion":157,"completion":911,"start":912,"conditions":913,"interventions":914},"NCT00004197","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",[89],"2003-11-20","1999-06-25",[16],[915,916,917,139,140,918,142,141],"keyhole limpet hemocyanin","sargramostim","tumor cell-based vaccine therapy","mitoxantrone hydrochloride",{"nctId":920,"briefTitle":921,"status":126,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":930},"NCT01093183","Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer",[88,89],"2015-05-19","2010-03-04",25,[927,928,929],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer",[931,139],"lenalidomide",{"nctId":765,"briefTitle":766,"status":153,"phases":933,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":934,"interventions":935},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"nctId":937,"briefTitle":938,"status":153,"phases":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":944},"NCT00002638","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia",[89],"2005-03","1995-03",30,[25],[945,916,170,139,171,172],"filgrastim",{"nctId":947,"briefTitle":948,"status":153,"phases":949,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":958},"NCT01106898","Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery",[89],"2015-09-28","2010-03-24",112,[954,955,956,957],"Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer",[139,886,959],"trastuzumab",{"nctId":961,"briefTitle":962,"status":126,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":968},"NCT00665457","Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery",[89],"2009-07-31","2004-04-15",3,[19],[945,969,970,139,971,140,144,778,888,889],"capecitabine","celecoxib","docetaxel",{"nctId":973,"briefTitle":974,"status":153,"phases":975,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":983},"NCT01336933","Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma",[89],"2016-12-28","2011-07-06",34,[980,981,982,743],"Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma",[142,139,172,984,985,986,144,987,988,143,989],"Vincristine","pralatrexate","comparative genomic hybridization","nucleic acid sequencing","mutation analysis","RNA analysis",{"nctId":38,"briefTitle":39,"status":689,"phases":991,"primaryCompletion":40,"completion":65,"start":992,"enrollment":993,"conditions":994,"interventions":1008},[89],"2012-12-07",92,[995,996,997,998,999,1000,1001,954,1002,956,957,1003,1004,1005,1006,1007],"Estrogen Receptor Negative","Estrogen Receptor Positive","HER2\u002FNeu Negative","HER2\u002FNeu Positive","Invasive Breast Carcinoma","Progesterone Receptor Negative","Progesterone Receptor Positive","Stage II Breast Cancer","Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Triple-Negative Breast Carcinoma",[41,1009,905,906],"Doxorubicin Hydrochloride",{"nctId":1011,"briefTitle":1012,"status":126,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":1016,"interventions":1018},"NCT00679029","Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)\u002FNeu-Negative Stage II\u002FIII Breast Cancer",[89],"2010-11-18","2008-05-02",[1017,1002,1004,1005,1006],"HER2-negative Breast Cancer",[140,139,1019,886,1020,1021],"bevacizumab","gemcitabine hydrochloride","pegfilgrastim",{"nctId":1023,"briefTitle":1024,"status":153,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":1028,"interventions":1038},"NCT02561273","Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma",[88,89],"2019-11-01","2020-11-01",[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],"Anaplastic Large Cell Lymphoma, ALK-Positive","Hepatosplenic T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Stage II Angioimmunoblastic T-cell Lymphoma","Stage II Enteropathy-Associated T-Cell Lymphoma","Stage III Angioimmunoblastic T-cell Lymphoma","Stage III Enteropathy-Associated T-Cell Lymphoma","Stage IV Angioimmunoblastic T-cell Lymphoma","Stage IV Enteropathy-Associated T-Cell Lymphoma",[41,1009,201,202,1039,1040],"Prednisone","Vincristine Sulfate",{"nctId":216,"briefTitle":217,"status":126,"phases":1042,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1043,"interventions":1044},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":1046,"activeCount":99},[1047],{"nctId":341,"briefTitle":342,"status":153,"phases":1048,"primaryCompletion":344,"completion":345,"start":346,"conditions":1049,"interventions":1050},[90],[16],[118,349,139,140,142,141],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"intervention":140,"totalTrials":119,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1063,"PHASE2":1076,"PHASE3":1102,"PHASE4":1108,"NA":1110},{"trials":1058,"activeCount":99},[1059],{"nctId":124,"briefTitle":125,"status":126,"phases":1060,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":1061,"interventions":1062},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":1064,"activeCount":99},[1065],{"nctId":1066,"briefTitle":1067,"status":153,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1074},"NCT00856037","Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer",[88],"2018-02-01","2009-02-02",22,[1073],"Recurrent Small Cell Lung Carcinoma",[1009,1075],"Topotecan Hydrochloride",{"trials":1077,"activeCount":95,"soonestReadout":40},[1078,1082,1086,1090,1094,1098],{"nctId":875,"briefTitle":876,"status":153,"phases":1079,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":1080,"interventions":1081},[89],[19],[884,885,139,140,886,887,144,888,889],{"nctId":908,"briefTitle":909,"status":153,"phases":1083,"primaryCompletion":157,"completion":911,"start":912,"conditions":1084,"interventions":1085},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":961,"briefTitle":962,"status":126,"phases":1087,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":1088,"interventions":1089},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"nctId":38,"briefTitle":39,"status":689,"phases":1091,"primaryCompletion":40,"completion":65,"start":992,"enrollment":993,"conditions":1092,"interventions":1093},[89],[995,996,997,998,999,1000,1001,954,1002,956,957,1003,1004,1005,1006,1007],[41,1009,905,906],{"nctId":1011,"briefTitle":1012,"status":126,"phases":1095,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":1096,"interventions":1097},[89],[1017,1002,1004,1005,1006],[140,139,1019,886,1020,1021],{"nctId":1023,"briefTitle":1024,"status":153,"phases":1099,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":1100,"interventions":1101},[88,89],[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],[41,1009,201,202,1039,1040],{"trials":1103,"activeCount":99},[1104],{"nctId":341,"briefTitle":342,"status":153,"phases":1105,"primaryCompletion":344,"completion":345,"start":346,"conditions":1106,"interventions":1107},[90],[16],[118,349,139,140,142,141],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"intervention":142,"totalTrials":705,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1120,"PHASE2":1122,"PHASE3":1147,"PHASE4":1153,"NA":1155},{"trials":1115,"activeCount":99},[1116],{"nctId":124,"briefTitle":125,"status":126,"phases":1117,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":1118,"interventions":1119},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":95,"soonestReadout":1132},[1124,1128,1139,1143],{"nctId":908,"briefTitle":909,"status":153,"phases":1125,"primaryCompletion":157,"completion":911,"start":912,"conditions":1126,"interventions":1127},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":1129,"briefTitle":1130,"status":109,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT07237269","Abi\u002FPred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer",[89],"2033-04-03","2026-04-03",140,[34],[1137,1138,1039],"Androgen Deprivation Therapy","Abiraterone",{"nctId":973,"briefTitle":974,"status":153,"phases":1140,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":1141,"interventions":1142},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"nctId":1023,"briefTitle":1024,"status":153,"phases":1144,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":1145,"interventions":1146},[88,89],[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],[41,1009,201,202,1039,1040],{"trials":1148,"activeCount":99},[1149],{"nctId":341,"briefTitle":342,"status":153,"phases":1150,"primaryCompletion":344,"completion":345,"start":346,"conditions":1151,"interventions":1152},[90],[16],[118,349,139,140,142,141],{"trials":1154,"activeCount":99},[],{"trials":1156,"activeCount":99},[],{"intervention":1158,"totalTrials":705,"cells":1159},"fluorouracil",{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1190,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[1164,1178],{"nctId":1165,"briefTitle":1166,"status":153,"phases":1167,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1175},"NCT01068327","Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer",[88],"2013-08-01","2015-02-01","2007-11-05",46,[1173,1174],"Adenocarcinoma of the Pancreas","Stage III Pancreatic Cancer",[1020,1176,1158,1177],"leucovorin calcium","nelfinavir mesylate",{"nctId":1179,"briefTitle":1180,"status":153,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1188},"NCT01206465","Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors",[88],"2015-02-04","2017-06-01","2010-09-14",29,[1187],"Unspecified Adult Solid Tumor, Protocol Specific",[985,1158,1189,777,987,778],"DNA analysis",{"trials":1191,"activeCount":95,"soonestReadout":1196},[1192,1213,1228,1247],{"nctId":1193,"briefTitle":1194,"status":689,"phases":1195,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":1171,"conditions":1198,"interventions":1209},"NCT03073785","Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer",[89],"2027-12","2016-09-16",[1199,1200,1201,1202,1203,1204,1205,1206,1207,1208],"Pancreatic Adenocarcinoma","Recurrent Pancreatic Carcinoma","Stage I Pancreatic Cancer AJCC v6 and v7","Stage IA Pancreatic Cancer AJCC v6 and v7","Stage IB Pancreatic Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage IIA Pancreatic Cancer AJCC v6 and v7","Stage IIB Pancreatic Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7",[1210,1211,1212],"Capecitabine","Fluorouracil","Zoledronic Acid",{"nctId":1214,"briefTitle":1215,"status":126,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":10,"conditions":1219,"interventions":1224},"NCT01307956","Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer",[89],"2015-12-23","2011-02-28",[1220,1221,1222,1223],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Adenocarcinoma","Stage IIA Esophageal Cancer","Stage IIB Esophageal Cancer",[1211,1225,1226,1227],"Leucovorin Calcium","Oxaliplatin","Panitumumab",{"nctId":1229,"briefTitle":1230,"status":153,"phases":1231,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":10,"conditions":1235,"interventions":1243},"NCT01959672","Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer",[89],"2018-04-01","2018-12-01","2013-09-06",[1199,1236,1237,1238,1239,1240,1241,1242,1174],"Resectable Pancreatic Carcinoma","Stage I Pancreatic Cancer","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage II Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer",[1211,1244,1225,1245,1246],"Gemcitabine Hydrochloride","Nelfinavir Mesylate","Oregovomab",{"nctId":1248,"briefTitle":1249,"status":153,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1185,"conditions":1254,"interventions":1256},"NCT00089024","Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",[89],"2010-01-22","2014-12-01","2004-02-25",[1255],"Pancreatic Cancer",[1158,1020,1176,1257],"oxaliplatin",{"trials":1259,"activeCount":99},[],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"intervention":886,"totalTrials":705,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":99},[],{"trials":1271,"activeCount":95,"soonestReadout":40},[1272,1276,1280,1291,1295,1299],{"nctId":875,"briefTitle":876,"status":153,"phases":1273,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":1274,"interventions":1275},[89],[19],[884,885,139,140,886,887,144,888,889],{"nctId":891,"briefTitle":892,"status":153,"phases":1277,"primaryCompletion":894,"completion":894,"start":895,"enrollment":222,"conditions":1278,"interventions":1279},[89],[897,898,899,900,901,902,903],[41,905,906],{"nctId":1281,"briefTitle":1282,"status":153,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":222,"conditions":1286,"interventions":1289},"NCT00602797","Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer",[89],"2014-08-01","2007-12-17",[1287,1288],"Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer",[905,1290],"Vinorelbine Tartrate",{"nctId":947,"briefTitle":948,"status":153,"phases":1292,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":1293,"interventions":1294},[89],[954,955,956,957],[139,886,959],{"nctId":38,"briefTitle":39,"status":689,"phases":1296,"primaryCompletion":40,"completion":65,"start":992,"enrollment":993,"conditions":1297,"interventions":1298},[89],[995,996,997,998,999,1000,1001,954,1002,956,957,1003,1004,1005,1006,1007],[41,1009,905,906],{"nctId":1011,"briefTitle":1012,"status":126,"phases":1300,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":1301,"interventions":1302},[89],[1017,1002,1004,1005,1006],[140,139,1019,886,1020,1021],{"trials":1304,"activeCount":99},[],{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"intervention":969,"totalTrials":771,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1339,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1312,"activeCount":99},[],{"trials":1314,"activeCount":99},[1315,1328],{"nctId":1316,"briefTitle":1317,"status":153,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1171,"conditions":1321,"interventions":1326},"NCT00486356","Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer",[88],"2010-01-01","2004-10-01",[1322,1323,1324,1325,1187],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer",[969,213,1327,143,778],"epirubicin hydrochloride",{"nctId":1329,"briefTitle":1330,"status":153,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1337},"NCT00483366","Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors",[88],"2009-01-30","2011-03-29","2006-08-15",13,[1187],[969,1020,1338,988,987,777],"imatinib mesylate",{"trials":1340,"activeCount":95,"soonestReadout":1196},[1341,1345,1349],{"nctId":1193,"briefTitle":1194,"status":689,"phases":1342,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":1171,"conditions":1343,"interventions":1344},[89],[1199,1200,1201,1202,1203,1204,1205,1206,1207,1208],[1210,1211,1212],{"nctId":961,"briefTitle":962,"status":126,"phases":1346,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":1347,"interventions":1348},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"nctId":1350,"briefTitle":1351,"status":126,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":20,"conditions":1355,"interventions":1357},"NCT02524275","Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[89],"2021-10-28","2015-03-30",[1356],"Head and Neck Squamous Cell Carcinoma",[1210,1358],"Docetaxel",{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"intervention":906,"totalTrials":966,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1368,"activeCount":99},[],{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":95,"soonestReadout":40},[1373,1377,1381],{"nctId":891,"briefTitle":892,"status":153,"phases":1374,"primaryCompletion":894,"completion":894,"start":895,"enrollment":222,"conditions":1375,"interventions":1376},[89],[897,898,899,900,901,902,903],[41,905,906],{"nctId":947,"briefTitle":948,"status":153,"phases":1378,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":1379,"interventions":1380},[89],[954,955,956,957],[139,886,959],{"nctId":38,"briefTitle":39,"status":689,"phases":1382,"primaryCompletion":40,"completion":65,"start":992,"enrollment":993,"conditions":1383,"interventions":1384},[89],[995,996,997,998,999,1000,1001,954,1002,956,957,1003,1004,1005,1006,1007],[41,1009,905,906],{"trials":1386,"activeCount":99},[],{"trials":1388,"activeCount":99},[],{"trials":1390,"activeCount":99},[],{"intervention":1392,"totalTrials":380,"cells":1393},"Oxytocin Intranasal Spray 24 International Unit",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":95,"soonestReadout":85},[1400,1410],{"nctId":1401,"briefTitle":1402,"status":109,"phases":1403,"primaryCompletion":85,"completion":816,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT06364228","Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia",[89],"2026-06-20",32,[1407],"Stress",[1409,1392],"Oxytocin Intranasal Spray 12 International Unit",{"nctId":1411,"briefTitle":1412,"status":126,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1419},"NCT03863288","Dose Response Relationship of Oxytocin on Irritability in Youths",[88,89],"2024-02-27","2022-02-18",60,[1418],"Irritable Mood",[1420,1421,1422,1423],"Oxytocin Intranasal Spray 8 International Unit","Oxytocin intranasal spray 24 International Unit","Oxytocin intranasal spray 48 International Unit","Oxytocin intranasal spray 80 International Unit",{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"intervention":56,"totalTrials":95,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":95,"soonestReadout":55},[1438],{"nctId":53,"briefTitle":54,"status":689,"phases":1439,"primaryCompletion":55,"completion":55,"start":1440,"enrollment":705,"conditions":1441,"interventions":1444},[88,89],"2021-07-15",[1442,1443],"Lung Cancer","Carcinoma, Non-Small Cell Lung",[56],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"intervention":761,"totalTrials":95,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":95,"soonestReadout":753},[1459],{"nctId":750,"briefTitle":751,"status":109,"phases":1460,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":1461,"interventions":1462},[89],[758,759],[761,762,763,747],{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"intervention":762,"totalTrials":95,"cells":1470},{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":95,"soonestReadout":753},[1477],{"nctId":750,"briefTitle":751,"status":109,"phases":1478,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":1479,"interventions":1480},[89],[758,759],[761,762,763,747],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"intervention":1137,"totalTrials":95,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":95,"soonestReadout":1132},[1495],{"nctId":1129,"briefTitle":1130,"status":109,"phases":1496,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1497,"interventions":1498},[89],[34],[1137,1138,1039],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"intervention":1138,"totalTrials":95,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":95,"soonestReadout":1132},[1513],{"nctId":1129,"briefTitle":1130,"status":109,"phases":1514,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1515,"interventions":1516},[89],[34],[1137,1138,1039],{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[],{"intervention":1524,"totalTrials":95,"cells":1525},"Cannabidiol Administered as Nantheia ATL5",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":95,"soonestReadout":1536},[1532],{"nctId":1533,"briefTitle":1534,"status":109,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":794,"conditions":1539,"interventions":1541},"NCT05269459","Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults",[89],"2028-12","2029-04","2022-12-01",[1540],"PTSD",[1524],{"trials":1543,"activeCount":99},[],{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"intervention":1549,"totalTrials":95,"cells":1550},"2 mL SunButyrate-TG",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":95,"soonestReadout":682},[1557],{"nctId":1558,"briefTitle":1559,"status":1560,"phases":1561,"primaryCompletion":682,"completion":691,"start":55,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT06882772","Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids","NOT_YET_RECRUITING",[88,89],105,[1564],"Congenital Heart Disease (CHD)",[1549,1566],"4 mL SunButyrate-TG",{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"intervention":1566,"totalTrials":95,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":95,"soonestReadout":682},[1581],{"nctId":1558,"briefTitle":1559,"status":1560,"phases":1582,"primaryCompletion":682,"completion":691,"start":55,"enrollment":1562,"conditions":1583,"interventions":1584},[88,89],[1564],[1549,1566],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[],{"trials":1590,"activeCount":99},[],{"intervention":1409,"totalTrials":95,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":95,"soonestReadout":85},[1599],{"nctId":1401,"briefTitle":1402,"status":109,"phases":1600,"primaryCompletion":85,"completion":816,"start":1404,"enrollment":1405,"conditions":1601,"interventions":1602},[89],[1407],[1409,1392],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[],{"intervention":1610,"totalTrials":95,"cells":1611},"Trabedersen",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1613,"activeCount":99},[],{"trials":1615,"activeCount":99},[],{"trials":1617,"activeCount":95,"soonestReadout":354},[1618],{"nctId":1619,"briefTitle":1620,"status":109,"phases":1621,"primaryCompletion":354,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1627},"NCT06579196","Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1",[88,89],"2029-02","2025-05-12",45,[1626],"Non-small Cell Lung Cancer",[1610,1628],"Pembrolizumab",{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":99},[],{"trials":1634,"activeCount":99},[],{"intervention":1628,"totalTrials":95,"cells":1636},{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":95,"soonestReadout":354},[1643],{"nctId":1619,"briefTitle":1620,"status":109,"phases":1644,"primaryCompletion":354,"completion":1622,"start":1623,"enrollment":1624,"conditions":1645,"interventions":1646},[88,89],[1626],[1610,1628],{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[],{"intervention":1654,"totalTrials":95,"cells":1655},"isotretinoin",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[],{"trials":1661,"activeCount":95,"soonestReadout":1667},[1662],{"nctId":1663,"briefTitle":1664,"status":1665,"phases":1666,"primaryCompletion":1667,"completion":1668,"start":1669,"enrollment":1670,"conditions":1671,"interventions":1675},"NCT07481370","Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm","ENROLLING_BY_INVITATION",[89],"2027-06-30","2027-12-31","2026-04-13",100,[1672,1673,1674],"Oligospermia","Azoospermia, Nonobstructive","Infertility",[1654,1676],"Human chorionic gonadotrophin",{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[],{"intervention":1676,"totalTrials":95,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":95,"soonestReadout":1667},[1691],{"nctId":1663,"briefTitle":1664,"status":1665,"phases":1692,"primaryCompletion":1667,"completion":1668,"start":1669,"enrollment":1670,"conditions":1693,"interventions":1694},[89],[1672,1673,1674],[1654,1676],{"trials":1696,"activeCount":99},[],{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"intervention":1702,"totalTrials":95,"cells":1703},"saline placebo",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1705,"activeCount":99},[],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":95,"soonestReadout":1714},[1710],{"nctId":1711,"briefTitle":1712,"status":1560,"phases":1713,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":222,"conditions":1717,"interventions":1722},"NCT06574048","Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy",[88,89],"2027-07","2028-01","2026-07",[1718,1719,1720,1721],"Carbon Monoxide Poisoning","Carbon Monoxide Intoxication","Carbon Monoxide Encephalopathy","Carbon Monoxide-induced Parkinsonism",[1702,1723],"Dexamethasone",{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[],{"intervention":1723,"totalTrials":95,"cells":1731},{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1736,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":99},[],{"trials":1737,"activeCount":95,"soonestReadout":1714},[1738],{"nctId":1711,"briefTitle":1712,"status":1560,"phases":1739,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":222,"conditions":1740,"interventions":1741},[88,89],[1718,1719,1720,1721],[1702,1723],{"trials":1743,"activeCount":99},[],{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[],{"intervention":76,"totalTrials":95,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1751,"activeCount":99},[],{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":95,"soonestReadout":75},[1756],{"nctId":73,"briefTitle":74,"status":689,"phases":1757,"primaryCompletion":75,"completion":1758,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1762},[89],"2032-09","2022-03-02",51,[19],[76],{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"intervention":51,"totalTrials":95,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":95,"soonestReadout":50},[1777],{"nctId":48,"briefTitle":49,"status":689,"phases":1778,"primaryCompletion":50,"completion":1779,"start":1780,"enrollment":1781,"conditions":1782,"interventions":1783},[89],"2031-01","2022-04-15",40,[32],[51],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[],{"intervention":1791,"totalTrials":95,"cells":1792},"Carmustine 7.7Mg Wafer",{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1794,"activeCount":99},[],{"trials":1796,"activeCount":99},[],{"trials":1798,"activeCount":95,"soonestReadout":1536},[1799],{"nctId":1800,"briefTitle":1801,"status":109,"phases":1802,"primaryCompletion":1536,"completion":691,"start":1803,"enrollment":1670,"conditions":1804,"interventions":1806},"NCT04222062","A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease",[89],"2020-11-06",[1805],"Brain Tumor - Metastatic",[1791],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"intervention":1212,"totalTrials":380,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":95,"soonestReadout":1196},[1821],{"nctId":1193,"briefTitle":1194,"status":689,"phases":1822,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":1171,"conditions":1823,"interventions":1824},[89],[1199,1200,1201,1202,1203,1204,1205,1206,1207,1208],[1210,1211,1212],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[1831],{"nctId":1832,"briefTitle":1833,"status":153,"phases":1834,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1837,"conditions":1838,"interventions":1840},"NCT00580047","Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney\u002FPancreas Transplants",[92],"2014-07-29","2003-12-01",59,[1839],"Renal Insufficiency",[1212,1841,1842],"Calcium with vitamin D","Alendronate",{"intervention":1844,"totalTrials":380,"cells":1845},"Temozolomide",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1875,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":95,"soonestReadout":1714},[1850,1864],{"nctId":1851,"briefTitle":1852,"status":109,"phases":1853,"primaryCompletion":1714,"completion":1854,"start":1855,"enrollment":693,"conditions":1856,"interventions":1862},"NCT05698524","A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma",[88],"2029-07","2023-06-26",[1857,1858,1859,1860,1861],"Recurrent High Grade Glioma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Glioblastoma","Gliosarcoma",[1863,1844],"PCI 24781",{"nctId":1865,"briefTitle":1866,"status":126,"phases":1867,"primaryCompletion":1868,"completion":1868,"start":1869,"enrollment":1870,"conditions":1871,"interventions":1873},"NCT02168270","Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma",[88],"2015-08-20","2014-06-16",4,[1858,1859,1872,1860,1861],"Anaplastic Oligoastrocytoma",[1874],"temozolomide",{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"intervention":1863,"totalTrials":95,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":95,"soonestReadout":1714},[1889],{"nctId":1851,"briefTitle":1852,"status":109,"phases":1890,"primaryCompletion":1714,"completion":1854,"start":1855,"enrollment":693,"conditions":1891,"interventions":1892},[88],[1857,1858,1859,1860,1861],[1863,1844],{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[],{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"intervention":1902,"totalTrials":95,"cells":1903},"Tamoxifen 20mg",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":95,"soonestReadout":1912},[1908],{"nctId":1909,"briefTitle":1910,"status":109,"phases":1911,"primaryCompletion":1912,"completion":1913,"start":1914,"enrollment":862,"conditions":1915,"interventions":1918},"NCT06320990","Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection",[88],"2028-11","2029-05","2025-01-22",[1916,1917],"Pancreatic Cyst","Pancreatic Mucinous Cystic Neoplasm",[1902],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"intervention":61,"totalTrials":95,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":95,"soonestReadout":60},[1933],{"nctId":58,"briefTitle":59,"status":689,"phases":1934,"primaryCompletion":60,"completion":60,"start":1935,"enrollment":693,"conditions":1936,"interventions":1941},[88],"2023-04-10",[1937,1938,1939,1940],"Pancreas Cancer","Biliary Tract Cancer","Psychological Distress","Gastrointestinal Cancer",[61],{"trials":1943,"activeCount":99},[],{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[],{"intervention":46,"totalTrials":95,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":95,"soonestReadout":45},[1956],{"nctId":43,"briefTitle":44,"status":689,"phases":1957,"primaryCompletion":45,"completion":1958,"start":1959,"enrollment":1960,"conditions":1961,"interventions":1969},[88],"2027-09","2023-03-21",33,[1962,1963,1964,1965,1966,1967,1968],"DLBCL - Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Follicular Lymphoma","Mediastinal Large B-cell Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma",[46],{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"intervention":71,"totalTrials":95,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1990,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1981,"activeCount":95,"soonestReadout":70},[1982],{"nctId":68,"briefTitle":69,"status":109,"phases":1983,"primaryCompletion":70,"completion":70,"start":1984,"enrollment":222,"conditions":1985,"interventions":1989},[87],"2024-11-14",[1986,1987,22,1988],"Peripheral Artery Disease","Peripheral Vascular Diseases","Peripheral Arterial Occlusive Disease",[71],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"intervention":331,"totalTrials":1870,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2016,"PHASE4":2018,"NA":2036},{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[],{"trials":2007,"activeCount":99},[2008,2012],{"nctId":765,"briefTitle":766,"status":153,"phases":2009,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":2010,"interventions":2011},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"nctId":216,"briefTitle":217,"status":126,"phases":2013,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":2014,"interventions":2015},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":2017,"activeCount":99},[],{"trials":2019,"activeCount":99},[2020,2024],{"nctId":788,"briefTitle":789,"status":153,"phases":2021,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":2022,"interventions":2023},[91],[796],[798,330,799,800,331],{"nctId":2025,"briefTitle":2026,"status":2027,"phases":2028,"completion":2029,"start":2030,"enrollment":1670,"conditions":2031,"interventions":2035},"NCT00564538","A Study of Thymoglobulin and Tacrolimus in Liver Transplant","UNKNOWN",[91],"2009-12","2007-12",[2032,2033,2034],"Liver Transplantation","Liver Disease","Immunosuppression",[332,331],{"trials":2037,"activeCount":99},[],{"intervention":332,"totalTrials":966,"cells":2039},{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2054,"PHASE4":2056,"NA":2062},{"trials":2041,"activeCount":99},[],{"trials":2043,"activeCount":99},[],{"trials":2045,"activeCount":99},[2046,2050],{"nctId":765,"briefTitle":766,"status":153,"phases":2047,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":2048,"interventions":2049},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"nctId":216,"briefTitle":217,"status":126,"phases":2051,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":2052,"interventions":2053},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":2055,"activeCount":99},[],{"trials":2057,"activeCount":99},[2058],{"nctId":2025,"briefTitle":2026,"status":2027,"phases":2059,"completion":2029,"start":2030,"enrollment":1670,"conditions":2060,"interventions":2061},[91],[2032,2033,2034],[332,331],{"trials":2063,"activeCount":99},[],{"intervention":2065,"totalTrials":380,"cells":2066},"Methylphenidate",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2098},{"trials":2068,"activeCount":99},[],{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[2077,2089],{"nctId":2078,"briefTitle":2079,"status":716,"phases":2080,"primaryCompletion":2081,"completion":2081,"start":2082,"enrollment":99,"conditions":2083,"interventions":2088},"NCT00792662","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",[91],"2011-12-20","2008-11-18",[2084,2085,2086,2087],"Diabetes Mellitus","Alzheimer's Disease","Apathy","Dementia",[2065],{"nctId":2090,"briefTitle":2091,"status":153,"phases":2092,"primaryCompletion":1319,"completion":1319,"start":2093,"enrollment":35,"conditions":2094,"interventions":2096},"NCT00754208","Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children",[91],"2008-09-18",[2095],"Attention Deficit Hyperactivity Disorder",[2097],"methylphenidate",{"trials":2099,"activeCount":99},[],{"intervention":2101,"totalTrials":380,"cells":2102},"Control Gel",{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2111,"NA":2132},{"trials":2104,"activeCount":99},[],{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[],{"trials":2110,"activeCount":99},[],{"trials":2112,"activeCount":99},[2113,2125],{"nctId":2114,"briefTitle":2115,"status":153,"phases":2116,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2123},"NCT05298202","The Influence of Capsaicin Gel During Exercise Within the Heat",[91],"2022-10-01","2022-05-25",12,[2121,2122],"Acute Exercise","Heat Exposure",[2124,2101],"Capsaicin",{"nctId":2126,"briefTitle":2127,"status":153,"phases":2128,"primaryCompletion":2117,"completion":2117,"start":40,"enrollment":2119,"conditions":2129,"interventions":2130},"NCT05302804","The Influence of Menthol Gel During Exercise With Heat",[91],[2121,2122],[2131,2101],"Menthol Gel",{"trials":2133,"activeCount":99},[],{"intervention":2135,"totalTrials":95,"cells":2136},"AGEE cream",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2145,"NA":2157},{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[2147],{"nctId":2148,"briefTitle":2149,"status":716,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":718,"enrollment":99,"conditions":2152,"interventions":2154},"NCT00988988","The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections",[91],"2012-08-03",[2153],"Multiple Sclerosis",[2135,2155,2156],"1% Steroid Cream","topical placebo cream with no active ingredients",{"trials":2158,"activeCount":99},[],{"intervention":2155,"totalTrials":95,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2175},{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[],{"trials":2166,"activeCount":99},[],{"trials":2168,"activeCount":99},[],{"trials":2170,"activeCount":99},[2171],{"nctId":2148,"briefTitle":2149,"status":716,"phases":2172,"primaryCompletion":2151,"completion":2151,"start":718,"enrollment":99,"conditions":2173,"interventions":2174},[91],[2153],[2135,2155,2156],{"trials":2176,"activeCount":99},[],{"intervention":2156,"totalTrials":95,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2193},{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"trials":2186,"activeCount":99},[],{"trials":2188,"activeCount":99},[2189],{"nctId":2148,"briefTitle":2149,"status":716,"phases":2190,"primaryCompletion":2151,"completion":2151,"start":718,"enrollment":99,"conditions":2191,"interventions":2192},[91],[2153],[2135,2155,2156],{"trials":2194,"activeCount":99},[],{"intervention":2196,"totalTrials":95,"cells":2197},"Prasugrel 10 mg daily x 2 weeks",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2219},{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[2208],{"nctId":2209,"briefTitle":2210,"status":153,"phases":2211,"primaryCompletion":2212,"completion":2213,"start":2214,"enrollment":942,"conditions":2215,"interventions":2217},"NCT01765400","Platelet Inhibition in Patients With Systolic Heart Failure",[91],"2015-12-01","2015-12-28","2013-05-15",[2216],"Systolic Heart Failure",[2196,2218],"Clopidogrel 75 mg daily x 2 weeks",{"trials":2220,"activeCount":99},[],{"intervention":2218,"totalTrials":95,"cells":2222},{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2237},{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[],{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[2233],{"nctId":2209,"briefTitle":2210,"status":153,"phases":2234,"primaryCompletion":2212,"completion":2213,"start":2214,"enrollment":942,"conditions":2235,"interventions":2236},[91],[2216],[2196,2218],{"trials":2238,"activeCount":99},[],{"intervention":2240,"totalTrials":95,"cells":2241},"Vitamin D",{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2262},{"trials":2243,"activeCount":99},[],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":99},[2252],{"nctId":2253,"briefTitle":2254,"status":126,"phases":2255,"primaryCompletion":2256,"completion":2256,"start":2257,"enrollment":771,"conditions":2258,"interventions":2261},"NCT03710161","Effect of Vitamin D Supplementation on Balance in CKD",[91],"2020-03-13","2019-07-08",[2259,2260],"Renal Insufficiency, Chronic","Kidney Failure, Chronic",[2240],{"trials":2263,"activeCount":99},[],{"intervention":2265,"totalTrials":95,"cells":2266},"Simvastatin-Methylcellulose",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2288},{"trials":2268,"activeCount":99},[],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[2277],{"nctId":2278,"briefTitle":2279,"status":153,"phases":2280,"primaryCompletion":2281,"completion":2282,"start":2283,"enrollment":2284,"conditions":2285,"interventions":2287},"NCT03452891","Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients",[91],"2020-07-31","2020-12-31","2019-03-01",50,[2286],"Periodontal Diseases",[2265],{"trials":2289,"activeCount":99},[],{"intervention":2291,"totalTrials":95,"cells":2292},"Norco",{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2301,"NA":2319},{"trials":2294,"activeCount":99},[],{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[2303],{"nctId":2304,"briefTitle":2305,"status":126,"phases":2306,"primaryCompletion":2307,"completion":2307,"start":2308,"enrollment":2309,"conditions":2310,"interventions":2315},"NCT02358850","Post-tonsillectomy Pain Control in Adults",[91],"2019-01-24","2016-01",27,[2311,2312,2313,2314],"Pain, Postoperative","Postoperative Nausea and Vomiting","Postoperative Hemorrhage","Body Weight Changes",[2291,2316,2317,2318],"Percocet","Dilaudid","Tylenol",{"trials":2320,"activeCount":99},[],{"intervention":2316,"totalTrials":95,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2337},{"trials":2324,"activeCount":99},[],{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[],{"trials":2332,"activeCount":99},[2333],{"nctId":2304,"briefTitle":2305,"status":126,"phases":2334,"primaryCompletion":2307,"completion":2307,"start":2308,"enrollment":2309,"conditions":2335,"interventions":2336},[91],[2311,2312,2313,2314],[2291,2316,2317,2318],{"trials":2338,"activeCount":99},[],{"intervention":2317,"totalTrials":95,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2355},{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[2351],{"nctId":2304,"briefTitle":2305,"status":126,"phases":2352,"primaryCompletion":2307,"completion":2307,"start":2308,"enrollment":2309,"conditions":2353,"interventions":2354},[91],[2311,2312,2313,2314],[2291,2316,2317,2318],{"trials":2356,"activeCount":99},[],{"intervention":2318,"totalTrials":95,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2373},{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[2369],{"nctId":2304,"briefTitle":2305,"status":126,"phases":2370,"primaryCompletion":2307,"completion":2307,"start":2308,"enrollment":2309,"conditions":2371,"interventions":2372},[91],[2311,2312,2313,2314],[2291,2316,2317,2318],{"trials":2374,"activeCount":99},[],{"intervention":2376,"totalTrials":95,"cells":2377},"Natrol",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2386,"NA":2396},{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[2388],{"nctId":2389,"briefTitle":2390,"status":126,"phases":2391,"primaryCompletion":2392,"completion":2392,"start":924,"enrollment":95,"conditions":2393,"interventions":2395},"NCT01033565","Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders",[91],"2010-10-01",[2394],"Sleep Disorder",[2376],{"trials":2397,"activeCount":99},[],{"intervention":2124,"totalTrials":95,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2414},{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[2410],{"nctId":2114,"briefTitle":2115,"status":153,"phases":2411,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":2119,"conditions":2412,"interventions":2413},[91],[2121,2122],[2124,2101],{"trials":2415,"activeCount":99},[],{"intervention":2417,"totalTrials":95,"cells":2418},"Contrave",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2440},{"trials":2420,"activeCount":99},[],{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":99},[2429],{"nctId":2430,"briefTitle":2431,"status":153,"phases":2432,"primaryCompletion":2433,"completion":2434,"start":2435,"enrollment":2436,"conditions":2437,"interventions":2438},"NCT03431831","Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic",[91],"2022-06-01","2022-07-01","2017-07-01",86,[30],[2417,2439],"Contrave and Counseling",{"trials":2441,"activeCount":99},[],{"intervention":2439,"totalTrials":95,"cells":2443},{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2452,"NA":2458},{"trials":2445,"activeCount":99},[],{"trials":2447,"activeCount":99},[],{"trials":2449,"activeCount":99},[],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[2454],{"nctId":2430,"briefTitle":2431,"status":153,"phases":2455,"primaryCompletion":2433,"completion":2434,"start":2435,"enrollment":2436,"conditions":2456,"interventions":2457},[91],[30],[2417,2439],{"trials":2459,"activeCount":99},[],{"intervention":2461,"totalTrials":95,"cells":2462},"Atomoxetine",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2484},{"trials":2464,"activeCount":99},[],{"trials":2466,"activeCount":99},[],{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[2473],{"nctId":2474,"briefTitle":2475,"status":153,"phases":2476,"primaryCompletion":2477,"completion":2478,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2483},"NCT00254462","Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children",[91],"2008-08-01","2008-09-01","2005-10-01",93,[2482],"Attention Deficit Disorder With Hyperactivity",[2461],{"trials":2485,"activeCount":99},[],{"intervention":2487,"totalTrials":95,"cells":2488},"Vanish XT Dental Varnish",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2507},{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[2499],{"nctId":2500,"briefTitle":2501,"status":716,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2503,"enrollment":99,"conditions":2504,"interventions":2506},"NCT03711097","Effectiveness of Resin-Modified Glass Ionomer Varnish in Preventing White Spot Lesions in Fixed Appliance Orthodontia",[91],"2019-04-22",[2505],"White Spot Lesion",[2487],{"trials":2508,"activeCount":99},[],{"intervention":2510,"totalTrials":95,"cells":2511},"ACEI continuation",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2534},{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[2522],{"nctId":2523,"briefTitle":2524,"status":153,"phases":2525,"primaryCompletion":2526,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT01669434","Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery",[91],"2016-11-01","2016-12-01","2015-06-01",291,[2531],"Hypotension on Induction",[2510,2533],"ACEI omission",{"trials":2535,"activeCount":99},[],{"intervention":2533,"totalTrials":95,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2544,"PHASE4":2546,"NA":2552},{"trials":2539,"activeCount":99},[],{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[2548],{"nctId":2523,"briefTitle":2524,"status":153,"phases":2549,"primaryCompletion":2526,"completion":2527,"start":2528,"enrollment":2529,"conditions":2550,"interventions":2551},[91],[2531],[2510,2533],{"trials":2553,"activeCount":99},[],{"intervention":798,"totalTrials":95,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2570},{"trials":2557,"activeCount":99},[],{"trials":2559,"activeCount":99},[],{"trials":2561,"activeCount":99},[],{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[2566],{"nctId":788,"briefTitle":789,"status":153,"phases":2567,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":2568,"interventions":2569},[91],[796],[798,330,799,800,331],{"trials":2571,"activeCount":99},[],{"intervention":799,"totalTrials":95,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2588},{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":99},[],{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[2584],{"nctId":788,"briefTitle":789,"status":153,"phases":2585,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":2586,"interventions":2587},[91],[796],[798,330,799,800,331],{"trials":2589,"activeCount":99},[],{"intervention":2591,"totalTrials":95,"cells":2592},"Sapropterin Dihydrochloride",{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2611},{"trials":2594,"activeCount":99},[],{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[2603],{"nctId":2604,"briefTitle":2605,"status":716,"phases":2606,"primaryCompletion":2607,"completion":2608,"start":2607,"enrollment":99,"conditions":2609,"interventions":2610},"NCT03493412","Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease",[91],"2019-07-01","2019-10-01",[1986,22],[2591],{"trials":2612,"activeCount":99},[],{"intervention":2614,"totalTrials":95,"cells":2615},"Bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2624,"NA":2637},{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[],{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[2626],{"nctId":2627,"briefTitle":2628,"status":153,"phases":2629,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":2634,"interventions":2636},"NCT03998176","Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (B\u002FF\u002FTAF) in HIV-1 Infected Patients With Active Illicit Substance usE",[91],"2021-10-01","2022-04-01","2019-10-09",43,[2635],"HIV-1-infection",[2614],{"trials":2638,"activeCount":99},[],{"intervention":2640,"totalTrials":95,"cells":2641},"Growth Hormone",{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2661},{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[],{"trials":2647,"activeCount":99},[],{"trials":2649,"activeCount":99},[],{"trials":2651,"activeCount":99},[2652],{"nctId":2653,"briefTitle":2654,"status":126,"phases":2655,"primaryCompletion":2656,"completion":2656,"start":2657,"enrollment":771,"conditions":2658,"interventions":2660},"NCT00742157","Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)",[91],"2008-10-20","2003-09-01",[2659],"Short Bowel Syndrome",[2640],{"trials":2662,"activeCount":99},[],{"intervention":2664,"totalTrials":95,"cells":2665},"harvoni",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2674,"NA":2687},{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"trials":2671,"activeCount":99},[],{"trials":2673,"activeCount":99},[],{"trials":2675,"activeCount":99},[2676],{"nctId":2677,"briefTitle":2678,"status":153,"phases":2679,"primaryCompletion":2680,"completion":2681,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2686},"NCT02759861","Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics",[91],"2020-08-01","2020-10-01","2016-08-01",16,[2685],"Genotype 1 Hepatitis C Virus",[2664],{"trials":2688,"activeCount":99},[],{"intervention":2690,"totalTrials":95,"cells":2691},"locally-applied minocycline HCl",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2710},{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":99},[2702],{"nctId":2703,"briefTitle":2704,"status":153,"phases":2705,"primaryCompletion":2212,"completion":2212,"start":2706,"enrollment":1416,"conditions":2707,"interventions":2709},"NCT01647282","Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients",[91],"2012-10-01",[2708],"Moderate to Advanced Chronic Periodontitis",[2690],{"trials":2711,"activeCount":99},[],{"intervention":2713,"totalTrials":95,"cells":2714},"Sufentanil",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2735},{"trials":2716,"activeCount":99},[],{"trials":2718,"activeCount":99},[],{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[2725],{"nctId":2726,"briefTitle":2727,"status":153,"phases":2728,"primaryCompletion":1353,"completion":1353,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2733},"NCT04226495","Sufentanil Infusion vs Sufentanil Bolus",[91],"2020-10-13",65,[2732],"Anesthesia",[2713,2734],"Sufentanil Bolus",{"trials":2736,"activeCount":99},[],{"intervention":2734,"totalTrials":95,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2745,"PHASE4":2747,"NA":2753},{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[2749],{"nctId":2726,"briefTitle":2727,"status":153,"phases":2750,"primaryCompletion":1353,"completion":1353,"start":2729,"enrollment":2730,"conditions":2751,"interventions":2752},[91],[2732],[2713,2734],{"trials":2754,"activeCount":99},[],{"intervention":2756,"totalTrials":95,"cells":2757},"Sitagliptin",{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2764,"PHASE4":2766,"NA":2779},{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[2768],{"nctId":2769,"briefTitle":2770,"status":126,"phases":2771,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":966,"conditions":2775,"interventions":2778},"NCT00936663","Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation",[91],"2010-05-01","2010-06-01","2009-07-06",[2776,2777],"Type 2 Diabetes","End Stage Renal Disease",[2756],{"trials":2780,"activeCount":99},[],{"intervention":2782,"totalTrials":95,"cells":2783},"lidocaine",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2804},{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[2794],{"nctId":2795,"briefTitle":2796,"status":126,"phases":2797,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":112,"conditions":2800,"interventions":2802},"NCT02647892","Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia",[91],"2021-11-05","2016-01-08",[2801],"Local Anesthesia",[2782,2803],"sodium bicarbonate",{"trials":2805,"activeCount":99},[],{"intervention":2131,"totalTrials":95,"cells":2807},{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2814,"PHASE4":2816,"NA":2822},{"trials":2809,"activeCount":99},[],{"trials":2811,"activeCount":99},[],{"trials":2813,"activeCount":99},[],{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[2818],{"nctId":2126,"briefTitle":2127,"status":153,"phases":2819,"primaryCompletion":2117,"completion":2117,"start":40,"enrollment":2119,"conditions":2820,"interventions":2821},[91],[2121,2122],[2131,2101],{"trials":2823,"activeCount":99},[],{"intervention":141,"totalTrials":1870,"cells":2825},{"EARLY_PHASE1":2826,"PHASE1":2832,"PHASE2":2834,"PHASE3":2844,"PHASE4":2850,"NA":2852},{"trials":2827,"activeCount":99},[2828],{"nctId":124,"briefTitle":125,"status":126,"phases":2829,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":2830,"interventions":2831},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[2836,2840],{"nctId":908,"briefTitle":909,"status":153,"phases":2837,"primaryCompletion":157,"completion":911,"start":912,"conditions":2838,"interventions":2839},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":1023,"briefTitle":1024,"status":153,"phases":2841,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":2842,"interventions":2843},[88,89],[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],[41,1009,201,202,1039,1040],{"trials":2845,"activeCount":99},[2846],{"nctId":341,"briefTitle":342,"status":153,"phases":2847,"primaryCompletion":344,"completion":345,"start":346,"conditions":2848,"interventions":2849},[90],[16],[118,349,139,140,142,141],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"intervention":2855,"totalTrials":95,"cells":2856},"Platelet rich plasma",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2874,"NA":2876},{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[2865],{"nctId":2866,"briefTitle":2867,"status":126,"phases":2868,"primaryCompletion":2869,"completion":2869,"start":2870,"enrollment":1335,"conditions":2871,"interventions":2873},"NCT04357353","The Role of Platelet Rich Plasma for Erectile Dysfunction",[90],"2022-11-02","2021-04-01",[2872],"Erectile Dysfunction",[2855],{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[],{"intervention":2879,"totalTrials":95,"cells":2880},"20 mg doxycycline hyclate",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2887,"PHASE4":2898,"NA":2900},{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[2889],{"nctId":2890,"briefTitle":2891,"status":153,"phases":2892,"primaryCompletion":2479,"completion":2479,"start":2893,"enrollment":2894,"conditions":2895,"interventions":2897},"NCT00066027","Effects of Low-Dose Doxycycline on Oral Bone Loss",[90],"2002-06-01",128,[2896],"Periodontitis",[2879],{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[],{"intervention":349,"totalTrials":95,"cells":2903},{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2910,"PHASE4":2916,"NA":2918},{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[2912],{"nctId":341,"briefTitle":342,"status":153,"phases":2913,"primaryCompletion":344,"completion":345,"start":346,"conditions":2914,"interventions":2915},[90],[16],[118,349,139,140,142,141],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"intervention":2921,"totalTrials":95,"cells":2922},"Intravenous Ketorolac",{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2929,"PHASE4":2942,"NA":2944},{"trials":2924,"activeCount":99},[],{"trials":2926,"activeCount":99},[],{"trials":2928,"activeCount":99},[],{"trials":2930,"activeCount":99},[2931],{"nctId":2932,"briefTitle":2933,"status":126,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":1960,"conditions":2937,"interventions":2940},"NCT04650893","The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF",[90],"2023-12-08","2021-01-02",[2938,2939],"Dysphagia","Dysphonia",[2921,2941],"Intravenous Dexamethasone",{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[],{"intervention":2941,"totalTrials":95,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2954,"PHASE4":2960,"NA":2962},{"trials":2949,"activeCount":99},[],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[2956],{"nctId":2932,"briefTitle":2933,"status":126,"phases":2957,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":1960,"conditions":2958,"interventions":2959},[90],[2938,2939],[2921,2941],{"trials":2961,"activeCount":99},[],{"trials":2963,"activeCount":99},[],{"intervention":2965,"totalTrials":95,"cells":2966},"Calcium Carbonate",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2986,"NA":2988},{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[2975],{"nctId":2976,"briefTitle":2977,"status":153,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":1169,"enrollment":2980,"conditions":2981,"interventions":2983},"NCT02186600","Heartland Osteoporosis Prevention Study",[90],"2019-06-01",276,[2982],"Osteopenia",[2965,2984,2985],"Vitamin D3","Risedronate",{"trials":2987,"activeCount":99},[],{"trials":2989,"activeCount":99},[],{"intervention":2984,"totalTrials":95,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3004,"NA":3006},{"trials":2993,"activeCount":99},[],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[],{"trials":2999,"activeCount":99},[3000],{"nctId":2976,"briefTitle":2977,"status":153,"phases":3001,"primaryCompletion":2979,"completion":2979,"start":1169,"enrollment":2980,"conditions":3002,"interventions":3003},[90],[2982],[2965,2984,2985],{"trials":3005,"activeCount":99},[],{"trials":3007,"activeCount":99},[],{"intervention":2985,"totalTrials":95,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3016,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":99},[],{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"trials":3017,"activeCount":99},[3018],{"nctId":2976,"briefTitle":2977,"status":153,"phases":3019,"primaryCompletion":2979,"completion":2979,"start":1169,"enrollment":2980,"conditions":3020,"interventions":3021},[90],[2982],[2965,2984,2985],{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":99},[],{"intervention":432,"totalTrials":95,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3034,"PHASE4":3040,"NA":3042},{"trials":3029,"activeCount":99},[],{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"trials":3035,"activeCount":99},[3036],{"nctId":424,"briefTitle":425,"status":153,"phases":3037,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":3038,"interventions":3039},[90],[28],[370,432,433],{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":99},[],{"intervention":433,"totalTrials":95,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3052,"PHASE4":3058,"NA":3060},{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[3054],{"nctId":424,"briefTitle":425,"status":153,"phases":3055,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":3056,"interventions":3057},[90],[28],[370,432,433],{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[],{"intervention":3063,"totalTrials":95,"cells":3064},"Regadenoson; Optison",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3071,"PHASE4":3083,"NA":3085},{"trials":3066,"activeCount":99},[],{"trials":3068,"activeCount":99},[],{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[3073],{"nctId":3074,"briefTitle":3075,"status":153,"phases":3076,"primaryCompletion":3077,"completion":1252,"start":3078,"enrollment":2284,"conditions":3079,"interventions":3082},"NCT01489176","Regadenoson Real Time Perfusion Imaging Trial-Optison",[90],"2014-04-01","2012-07-31",[3080,3081],"Coronary Artery Disease","Myocardial Perfusion Abnormalities",[3063],{"trials":3084,"activeCount":99},[],{"trials":3086,"activeCount":99},[],{"intervention":403,"totalTrials":95,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[3097],{"nctId":395,"briefTitle":396,"status":153,"phases":3098,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":3099,"interventions":3100},[90],[28],[403,404],{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[],{"intervention":172,"totalTrials":119,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[3113,3117,3121,3125,3134,3138,3142,3146,3158],{"nctId":162,"briefTitle":163,"status":153,"phases":3114,"primaryCompletion":155,"completion":165,"start":166,"enrollment":167,"conditions":3115,"interventions":3116},[89],[16],[118,170,171,172,173],{"nctId":175,"briefTitle":176,"status":153,"phases":3118,"primaryCompletion":157,"completion":178,"start":179,"enrollment":180,"conditions":3119,"interventions":3120},[89],[16],[118,170,171,172,173],{"nctId":184,"briefTitle":185,"status":153,"phases":3122,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":3123,"interventions":3124},[88,89],[192,193,194,195,196,197],[199,200,201,202,203,204],{"nctId":3126,"briefTitle":3127,"status":153,"phases":3128,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":2284,"conditions":3132,"interventions":3133},"NCT00006695","Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma",[89],"2005-09-01","2014-12-16","2000-04-01",[16],[170,171,172,173],{"nctId":206,"briefTitle":207,"status":153,"phases":3135,"primaryCompletion":209,"completion":210,"start":179,"conditions":3136,"interventions":3137},[89],[16],[118,213,172,214],{"nctId":937,"briefTitle":938,"status":153,"phases":3139,"completion":940,"start":941,"enrollment":942,"conditions":3140,"interventions":3141},[89],[25],[945,916,170,139,171,172],{"nctId":973,"briefTitle":974,"status":153,"phases":3143,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":3144,"interventions":3145},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"nctId":3147,"briefTitle":3148,"status":153,"phases":3149,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":3153,"interventions":3155},"NCT00004192","Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma",[89],"2001-02-01","2001-03-16","2000-05-01",[16,3154],"Neutropenia",[945,1021,3156,171,172,3157],"cisplatin","methylprednisolone",{"nctId":1023,"briefTitle":1024,"status":153,"phases":3159,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":3160,"interventions":3161},[88,89],[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],[41,1009,201,202,1039,1040],{"trials":3163,"activeCount":99},[],{"trials":3165,"activeCount":99},[],{"trials":3167,"activeCount":99},[],{"intervention":171,"totalTrials":26,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3174,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[],{"trials":3175,"activeCount":99},[3176,3180,3184,3188,3192,3196,3205,3224],{"nctId":162,"briefTitle":163,"status":153,"phases":3177,"primaryCompletion":155,"completion":165,"start":166,"enrollment":167,"conditions":3178,"interventions":3179},[89],[16],[118,170,171,172,173],{"nctId":175,"briefTitle":176,"status":153,"phases":3181,"primaryCompletion":157,"completion":178,"start":179,"enrollment":180,"conditions":3182,"interventions":3183},[89],[16],[118,170,171,172,173],{"nctId":184,"briefTitle":185,"status":153,"phases":3185,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":3186,"interventions":3187},[88,89],[192,193,194,195,196,197],[199,200,201,202,203,204],{"nctId":3126,"briefTitle":3127,"status":153,"phases":3189,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":2284,"conditions":3190,"interventions":3191},[89],[16],[170,171,172,173],{"nctId":937,"briefTitle":938,"status":153,"phases":3193,"completion":940,"start":941,"enrollment":942,"conditions":3194,"interventions":3195},[89],[25],[945,916,170,139,171,172],{"nctId":3197,"briefTitle":3198,"status":126,"phases":3199,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":380,"conditions":3202,"interventions":3203},"NCT00503880","Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes",[88,89],"2009-10-13","2007-05-07",[722],[945,3204,171,143],"clofarabine",{"nctId":3206,"briefTitle":3207,"status":153,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3217},"NCT03226418","Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia",[89],"2024-03-16","2024-10-01","2017-07-07",75,[3214,3215,3216],"Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Acute Myeloid Leukemia",[200,3218,3219,3220,3221,3222,3223],"Decitabine","Idarubicin","Liposome-encapsulated Daunorubicin-Cytarabine","Azacitidine","Venetoclax","glasdegib",{"nctId":3147,"briefTitle":3148,"status":153,"phases":3225,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":3226,"interventions":3227},[89],[16,3154],[945,1021,3156,171,172,3157],{"trials":3229,"activeCount":99},[],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[],{"intervention":916,"totalTrials":35,"cells":3235},{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3268,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3237,"activeCount":99},[],{"trials":3239,"activeCount":99},[3240,3248,3259],{"nctId":3241,"briefTitle":3242,"status":153,"phases":3243,"primaryCompletion":3210,"completion":3210,"start":3244,"enrollment":35,"conditions":3245,"interventions":3247},"NCT03790670","Biomarker Assessments of Leukine During Treatment of Parkinson's Disease",[88],"2019-01-30",[3246],"Parkinson Disease",[916],{"nctId":3249,"briefTitle":3250,"status":153,"phases":3251,"primaryCompletion":3252,"completion":3253,"start":3254,"enrollment":10,"conditions":3255,"interventions":3257},"NCT05677633","Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease",[88],"2024-04-12","2024-11-01","2023-01-19",[3256],"Parkinson's Disease and Parkinsonism",[3258],"Sargramostim",{"nctId":3260,"briefTitle":3261,"status":153,"phases":3262,"primaryCompletion":3263,"completion":3263,"start":3264,"enrollment":130,"conditions":3265,"interventions":3267},"NCT01882010","Leukine (Sargramostim) for Parkinson's Disease",[88],"2016-01-01","2013-09-01",[3266],"Parkinson's Disease",[916],{"trials":3269,"activeCount":99},[3270,3280,3284,3288],{"nctId":3271,"briefTitle":3272,"status":126,"phases":3273,"primaryCompletion":3274,"completion":3274,"start":3275,"enrollment":3276,"conditions":3277,"interventions":3278},"NCT00006478","Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma",[89],"2008-04-03","2000-10-11",19,[16],[3279,915,916],"autologous tumor cell vaccine",{"nctId":908,"briefTitle":909,"status":153,"phases":3281,"primaryCompletion":157,"completion":911,"start":912,"conditions":3282,"interventions":3283},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":937,"briefTitle":938,"status":153,"phases":3285,"completion":940,"start":941,"enrollment":942,"conditions":3286,"interventions":3287},[89],[25],[945,916,170,139,171,172],{"nctId":3289,"briefTitle":3290,"status":153,"phases":3291,"primaryCompletion":157,"completion":911,"start":912,"conditions":3292,"interventions":3293},"NCT00004198","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma",[89],[16],[915,916,917],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"intervention":1020,"totalTrials":705,"cells":3301},{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3341,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3303,"activeCount":99},[],{"trials":3305,"activeCount":99},[3306,3310,3337],{"nctId":1165,"briefTitle":1166,"status":153,"phases":3307,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":3308,"interventions":3309},[88],[1173,1174],[1020,1176,1158,1177],{"nctId":3311,"briefTitle":3312,"status":153,"phases":3313,"primaryCompletion":1183,"completion":1183,"start":3314,"enrollment":881,"conditions":3315,"interventions":3334},"NCT01825603","ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer",[88],"2013-04-09",[3316,3317,3318,1199,3319,3320,1174,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332,3333],"Ampulla of Vater Adenocarcinoma","Gallbladder Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage III Ampulla of Vater Cancer","Stage III Intrahepatic Cholangiocarcinoma","Stage IIIA Gallbladder Cancer","Stage IIIA Hilar Cholangiocarcinoma","Stage IIIB Gallbladder Cancer","Stage IIIB Hilar Cholangiocarcinoma","Stage IV Ampulla of Vater Cancer","Stage IVA Gallbladder Cancer","Stage IVA Hilar Cholangiocarcinoma","Stage IVA Intrahepatic Cholangiocarcinoma","Stage IVA Pancreatic Cancer","Stage IVB Gallbladder Cancer","Stage IVB Hilar Cholangiocarcinoma","Stage IVB Intrahepatic Cholangiocarcinoma","Stage IVB Pancreatic Cancer",[3335,3336,1244],"ADH-1","Cisplatin",{"nctId":1329,"briefTitle":1330,"status":153,"phases":3338,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":3339,"interventions":3340},[88],[1187],[969,1020,1338,988,987,777],{"trials":3342,"activeCount":99},[3343,3347,3351],{"nctId":1229,"briefTitle":1230,"status":153,"phases":3344,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":10,"conditions":3345,"interventions":3346},[89],[1199,1236,1237,1238,1239,1240,1241,1242,1174],[1211,1244,1225,1245,1246],{"nctId":1248,"briefTitle":1249,"status":153,"phases":3348,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1185,"conditions":3349,"interventions":3350},[89],[1255],[1158,1020,1176,1257],{"nctId":1011,"briefTitle":1012,"status":126,"phases":3352,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":3353,"interventions":3354},[89],[1017,1002,1004,1005,1006],[140,139,1019,886,1020,1021],{"trials":3356,"activeCount":99},[],{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"intervention":173,"totalTrials":771,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[3369,3380,3384,3388,3392],{"nctId":3370,"briefTitle":3371,"status":126,"phases":3372,"primaryCompletion":3373,"completion":3373,"start":3374,"enrollment":26,"conditions":3375,"interventions":3377},"NCT02700841","Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation",[89],"2022-12-21","2020-01-09",[3376],"Plasma Cell Myeloma",[203,3378,3379],"T Cell-Depleted Hematopoietic Stem Cell Transplantation","Tetanus Toxoid Vaccine",{"nctId":162,"briefTitle":163,"status":153,"phases":3381,"primaryCompletion":155,"completion":165,"start":166,"enrollment":167,"conditions":3382,"interventions":3383},[89],[16],[118,170,171,172,173],{"nctId":175,"briefTitle":176,"status":153,"phases":3385,"primaryCompletion":157,"completion":178,"start":179,"enrollment":180,"conditions":3386,"interventions":3387},[89],[16],[118,170,171,172,173],{"nctId":184,"briefTitle":185,"status":153,"phases":3389,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":3390,"interventions":3391},[88,89],[192,193,194,195,196,197],[199,200,201,202,203,204],{"nctId":3126,"briefTitle":3127,"status":153,"phases":3393,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":2284,"conditions":3394,"interventions":3395},[89],[16],[170,171,172,173],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[],{"trials":3401,"activeCount":99},[],{"intervention":170,"totalTrials":771,"cells":3403},{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3405,"activeCount":99},[],{"trials":3407,"activeCount":99},[],{"trials":3409,"activeCount":99},[3410,3414,3418,3422,3426],{"nctId":162,"briefTitle":163,"status":153,"phases":3411,"primaryCompletion":155,"completion":165,"start":166,"enrollment":167,"conditions":3412,"interventions":3413},[89],[16],[118,170,171,172,173],{"nctId":175,"briefTitle":176,"status":153,"phases":3415,"primaryCompletion":157,"completion":178,"start":179,"enrollment":180,"conditions":3416,"interventions":3417},[89],[16],[118,170,171,172,173],{"nctId":184,"briefTitle":185,"status":153,"phases":3419,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":3420,"interventions":3421},[88,89],[192,193,194,195,196,197],[199,200,201,202,203,204],{"nctId":3126,"briefTitle":3127,"status":153,"phases":3423,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":2284,"conditions":3424,"interventions":3425},[89],[16],[170,171,172,173],{"nctId":937,"briefTitle":938,"status":153,"phases":3427,"completion":940,"start":941,"enrollment":942,"conditions":3428,"interventions":3429},[89],[25],[945,916,170,139,171,172],{"trials":3431,"activeCount":99},[],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"intervention":1176,"totalTrials":1870,"cells":3437},{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3446,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":99},[3442],{"nctId":1165,"briefTitle":1166,"status":153,"phases":3443,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":3444,"interventions":3445},[88],[1173,1174],[1020,1176,1158,1177],{"trials":3447,"activeCount":99},[3448,3452,3456],{"nctId":1214,"briefTitle":1215,"status":126,"phases":3449,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":10,"conditions":3450,"interventions":3451},[89],[1220,1221,1222,1223],[1211,1225,1226,1227],{"nctId":1229,"briefTitle":1230,"status":153,"phases":3453,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":10,"conditions":3454,"interventions":3455},[89],[1199,1236,1237,1238,1239,1240,1241,1242,1174],[1211,1244,1225,1245,1246],{"nctId":1248,"briefTitle":1249,"status":153,"phases":3457,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1185,"conditions":3458,"interventions":3459},[89],[1255],[1158,1020,1176,1257],{"trials":3461,"activeCount":99},[],{"trials":3463,"activeCount":99},[],{"trials":3465,"activeCount":99},[],{"intervention":778,"totalTrials":1870,"cells":3467},{"EARLY_PHASE1":3468,"PHASE1":3470,"PHASE2":3480,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3469,"activeCount":99},[],{"trials":3471,"activeCount":99},[3472,3476],{"nctId":1179,"briefTitle":1180,"status":153,"phases":3473,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":3474,"interventions":3475},[88],[1187],[985,1158,1189,777,987,778],{"nctId":1316,"briefTitle":1317,"status":153,"phases":3477,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1171,"conditions":3478,"interventions":3479},[88],[1322,1323,1324,1325,1187],[969,213,1327,143,778],{"trials":3481,"activeCount":99},[3482,3486],{"nctId":765,"briefTitle":766,"status":153,"phases":3483,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":3484,"interventions":3485},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"nctId":961,"briefTitle":962,"status":126,"phases":3487,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":3488,"interventions":3489},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"intervention":202,"totalTrials":1870,"cells":3497},{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3502,"PHASE3":3527,"PHASE4":3529,"NA":3531},{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[3504,3508,3512,3523],{"nctId":184,"briefTitle":185,"status":153,"phases":3505,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":3506,"interventions":3507},[88,89],[192,193,194,195,196,197],[199,200,201,202,203,204],{"nctId":920,"briefTitle":921,"status":126,"phases":3509,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":3510,"interventions":3511},[88,89],[927,928,929],[931,139],{"nctId":3513,"briefTitle":3514,"status":153,"phases":3515,"primaryCompletion":3516,"completion":3517,"start":3518,"enrollment":1171,"conditions":3519,"interventions":3521},"NCT01060384","Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma",[88,89],"2016-10-25","2018-01-01","2010-03-29",[3520],"Non-Hodgkin's Lymphoma",[202,3522],"ofatumumab",{"nctId":1023,"briefTitle":1024,"status":153,"phases":3524,"primaryCompletion":1026,"completion":1027,"start":950,"enrollment":12,"conditions":3525,"interventions":3526},[88,89],[192,1029,1030,1031,1032,1033,1034,1035,1036,1037],[41,1009,201,202,1039,1040],{"trials":3528,"activeCount":99},[],{"trials":3530,"activeCount":99},[],{"trials":3532,"activeCount":99},[],{"intervention":143,"totalTrials":1870,"cells":3534},{"EARLY_PHASE1":3535,"PHASE1":3541,"PHASE2":3547,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3536,"activeCount":99},[3537],{"nctId":124,"briefTitle":125,"status":126,"phases":3538,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":3539,"interventions":3540},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":3542,"activeCount":99},[3543],{"nctId":1316,"briefTitle":1317,"status":153,"phases":3544,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1171,"conditions":3545,"interventions":3546},[88],[1322,1323,1324,1325,1187],[969,213,1327,143,778],{"trials":3548,"activeCount":99},[3549,3553],{"nctId":973,"briefTitle":974,"status":153,"phases":3550,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":3551,"interventions":3552},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"nctId":3197,"briefTitle":3198,"status":126,"phases":3554,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":380,"conditions":3555,"interventions":3556},[88,89],[722],[945,3204,171,143],{"trials":3558,"activeCount":99},[],{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[],{"intervention":945,"totalTrials":1870,"cells":3564},{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3587,"PHASE4":3589,"NA":3591},{"trials":3566,"activeCount":99},[],{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":99},[3571,3575,3579,3583],{"nctId":937,"briefTitle":938,"status":153,"phases":3572,"completion":940,"start":941,"enrollment":942,"conditions":3573,"interventions":3574},[89],[25],[945,916,170,139,171,172],{"nctId":961,"briefTitle":962,"status":126,"phases":3576,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":3577,"interventions":3578},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"nctId":3197,"briefTitle":3198,"status":126,"phases":3580,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":380,"conditions":3581,"interventions":3582},[88,89],[722],[945,3204,171,143],{"nctId":3147,"briefTitle":3148,"status":153,"phases":3584,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":3585,"interventions":3586},[89],[16,3154],[945,1021,3156,171,172,3157],{"trials":3588,"activeCount":99},[],{"trials":3590,"activeCount":99},[],{"trials":3592,"activeCount":99},[],{"intervention":915,"totalTrials":966,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"trials":3600,"activeCount":99},[3601,3605,3609],{"nctId":3271,"briefTitle":3272,"status":126,"phases":3602,"primaryCompletion":3274,"completion":3274,"start":3275,"enrollment":3276,"conditions":3603,"interventions":3604},[89],[16],[3279,915,916],{"nctId":908,"briefTitle":909,"status":153,"phases":3606,"primaryCompletion":157,"completion":911,"start":912,"conditions":3607,"interventions":3608},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":3289,"briefTitle":3290,"status":153,"phases":3610,"primaryCompletion":157,"completion":911,"start":912,"conditions":3611,"interventions":3612},[89],[16],[915,916,917],{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"trials":3618,"activeCount":99},[],{"intervention":1226,"totalTrials":966,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[],{"trials":3626,"activeCount":99},[3627,3639,3643],{"nctId":3628,"briefTitle":3629,"status":126,"phases":3630,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":10,"conditions":3633,"interventions":3634},"NCT04141995","FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer",[89],"2025-05-13","2021-02-12",[1937,1173],[3635,3636,3637,3638,1226],"Digoxin","5Fluorouracil","Calcium Leucovorin","Irinotecan",{"nctId":1214,"briefTitle":1215,"status":126,"phases":3640,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":10,"conditions":3641,"interventions":3642},[89],[1220,1221,1222,1223],[1211,1225,1226,1227],{"nctId":1248,"briefTitle":1249,"status":153,"phases":3644,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1185,"conditions":3645,"interventions":3646},[89],[1255],[1158,1020,1176,1257],{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"trials":3652,"activeCount":99},[],{"intervention":777,"totalTrials":966,"cells":3654},{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3667,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[3659,3663],{"nctId":1179,"briefTitle":1180,"status":153,"phases":3660,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":3661,"interventions":3662},[88],[1187],[985,1158,1189,777,987,778],{"nctId":1329,"briefTitle":1330,"status":153,"phases":3664,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":3665,"interventions":3666},[88],[1187],[969,1020,1338,988,987,777],{"trials":3668,"activeCount":99},[3669],{"nctId":765,"briefTitle":766,"status":153,"phases":3670,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":3671,"interventions":3672},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"trials":3674,"activeCount":99},[],{"trials":3676,"activeCount":99},[],{"trials":3678,"activeCount":99},[],{"intervention":987,"totalTrials":966,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3693,"PHASE3":3699,"PHASE4":3701,"NA":3703},{"trials":3682,"activeCount":99},[],{"trials":3684,"activeCount":99},[3685,3689],{"nctId":1179,"briefTitle":1180,"status":153,"phases":3686,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":3687,"interventions":3688},[88],[1187],[985,1158,1189,777,987,778],{"nctId":1329,"briefTitle":1330,"status":153,"phases":3690,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":3691,"interventions":3692},[88],[1187],[969,1020,1338,988,987,777],{"trials":3694,"activeCount":99},[3695],{"nctId":973,"briefTitle":974,"status":153,"phases":3696,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":3697,"interventions":3698},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":3700,"activeCount":99},[],{"trials":3702,"activeCount":99},[],{"trials":3704,"activeCount":99},[],{"intervention":3706,"totalTrials":966,"cells":3707},"BEAM",{"EARLY_PHASE1":3708,"PHASE1":3710,"PHASE2":3721,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3709,"activeCount":99},[],{"trials":3711,"activeCount":99},[3712],{"nctId":3713,"briefTitle":3714,"status":153,"phases":3715,"primaryCompletion":3716,"completion":3717,"start":3718,"enrollment":978,"conditions":3719,"interventions":3720},"NCT00574509","Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma",[88],"2014-11-01","2014-12-10","1996-03-04",[16],[3706],{"trials":3722,"activeCount":99},[3723,3734],{"nctId":3724,"briefTitle":3725,"status":153,"phases":3726,"primaryCompletion":3716,"completion":3716,"start":3727,"enrollment":3728,"conditions":3729,"interventions":3732},"NCT00571493","VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma",[88,89],"2006-04-14",42,[3730,3731],"Non-hodgkin's Lymphoma","Mantle Cell Lymphoma",[3733,3706],"Bortezomib",{"nctId":3735,"briefTitle":3736,"status":153,"phases":3737,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":1405,"conditions":3741,"interventions":3742},"NCT00572013","Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma",[88,89],"2001-01-01","2009-09-18","1998-05-12",[16],[3743,3706],"Rituxan",{"trials":3745,"activeCount":99},[],{"trials":3747,"activeCount":99},[],{"trials":3749,"activeCount":99},[],{"intervention":971,"totalTrials":966,"cells":3751},{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3766,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3753,"activeCount":99},[],{"trials":3755,"activeCount":99},[3756],{"nctId":3757,"briefTitle":3758,"status":153,"phases":3759,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":119,"conditions":3762,"interventions":3763},"NCT00482807","Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer",[88],"2010-03-09","2004-08-31",[34],[3764,971,3765],"bicalutamide","goserelin",{"trials":3767,"activeCount":99},[3768,3772],{"nctId":961,"briefTitle":962,"status":126,"phases":3769,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":3770,"interventions":3771},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"nctId":1350,"briefTitle":1351,"status":126,"phases":3773,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":20,"conditions":3774,"interventions":3775},[89],[1356],[1210,1358],{"trials":3777,"activeCount":99},[],{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[],{"intervention":726,"totalTrials":380,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3785,"activeCount":99},[],{"trials":3787,"activeCount":99},[],{"trials":3789,"activeCount":99},[3790,3794],{"nctId":714,"briefTitle":715,"status":716,"phases":3791,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":3792,"interventions":3793},[88,89],[721,25,16,722,723],[725,330,726,145,727,728],{"nctId":730,"briefTitle":731,"status":153,"phases":3795,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":3796,"interventions":3797},[89],[737,738,739,740,722,32,741,742,743],[745,746,747,748],{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"intervention":145,"totalTrials":380,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3812,"PHASE2":3814,"PHASE3":3820,"PHASE4":3822,"NA":3824},{"trials":3807,"activeCount":99},[3808],{"nctId":124,"briefTitle":125,"status":126,"phases":3809,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":3810,"interventions":3811},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":3813,"activeCount":99},[],{"trials":3815,"activeCount":99},[3816],{"nctId":714,"briefTitle":715,"status":716,"phases":3817,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":3818,"interventions":3819},[88,89],[721,25,16,722,723],[725,330,726,145,727,728],{"trials":3821,"activeCount":99},[],{"trials":3823,"activeCount":99},[],{"trials":3825,"activeCount":99},[],{"intervention":1177,"totalTrials":380,"cells":3827},{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3836,"PHASE3":3842,"PHASE4":3844,"NA":3846},{"trials":3829,"activeCount":99},[],{"trials":3831,"activeCount":99},[3832],{"nctId":1165,"briefTitle":1166,"status":153,"phases":3833,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":3834,"interventions":3835},[88],[1173,1174],[1020,1176,1158,1177],{"trials":3837,"activeCount":99},[3838],{"nctId":1229,"briefTitle":1230,"status":153,"phases":3839,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":10,"conditions":3840,"interventions":3841},[89],[1199,1236,1237,1238,1239,1240,1241,1242,1174],[1211,1244,1225,1245,1246],{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[],{"intervention":888,"totalTrials":380,"cells":3849},{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3864,"PHASE4":3866,"NA":3868},{"trials":3851,"activeCount":99},[],{"trials":3853,"activeCount":99},[],{"trials":3855,"activeCount":99},[3856,3860],{"nctId":875,"briefTitle":876,"status":153,"phases":3857,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":3858,"interventions":3859},[89],[19],[884,885,139,140,886,887,144,888,889],{"nctId":961,"briefTitle":962,"status":126,"phases":3861,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":3862,"interventions":3863},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"trials":3865,"activeCount":99},[],{"trials":3867,"activeCount":99},[],{"trials":3869,"activeCount":99},[],{"intervention":889,"totalTrials":380,"cells":3871},{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3886,"PHASE4":3888,"NA":3890},{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[3878,3882],{"nctId":875,"briefTitle":876,"status":153,"phases":3879,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":3880,"interventions":3881},[89],[19],[884,885,139,140,886,887,144,888,889],{"nctId":961,"briefTitle":962,"status":126,"phases":3883,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":3884,"interventions":3885},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"trials":3887,"activeCount":99},[],{"trials":3889,"activeCount":99},[],{"trials":3891,"activeCount":99},[],{"intervention":985,"totalTrials":380,"cells":3893},{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3902,"PHASE3":3908,"PHASE4":3910,"NA":3912},{"trials":3895,"activeCount":99},[],{"trials":3897,"activeCount":99},[3898],{"nctId":1179,"briefTitle":1180,"status":153,"phases":3899,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":3900,"interventions":3901},[88],[1187],[985,1158,1189,777,987,778],{"trials":3903,"activeCount":99},[3904],{"nctId":973,"briefTitle":974,"status":153,"phases":3905,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":3906,"interventions":3907},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":3909,"activeCount":99},[],{"trials":3911,"activeCount":99},[],{"trials":3913,"activeCount":99},[],{"intervention":3915,"totalTrials":380,"cells":3916},"Latanoprost",{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3921,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3918,"activeCount":99},[],{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[3923,3933],{"nctId":3924,"briefTitle":3925,"status":126,"phases":3926,"primaryCompletion":3927,"completion":3927,"start":3928,"enrollment":942,"conditions":3929,"interventions":3931},"NCT00579969","Comparison of Latanoprost Vs. Timolol",[89],"2008-10","2003-12",[3930],"Glaucoma",[3915,3932],"Timolol",{"nctId":3934,"briefTitle":3935,"status":153,"phases":3936,"primaryCompletion":3937,"completion":3937,"start":3938,"enrollment":942,"conditions":3939,"interventions":3940},"NCT00572936","Circadian Rhythms of Aqueous Humor Dynamics in Humans",[89],"2009-11-01","2006-03-13",[3930],[3915,3941,3932],"Dorzolamide",{"trials":3943,"activeCount":99},[],{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[],{"intervention":3932,"totalTrials":380,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3954,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3951,"activeCount":99},[],{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[3956,3960],{"nctId":3924,"briefTitle":3925,"status":126,"phases":3957,"primaryCompletion":3927,"completion":3927,"start":3928,"enrollment":942,"conditions":3958,"interventions":3959},[89],[3930],[3915,3932],{"nctId":3934,"briefTitle":3935,"status":153,"phases":3961,"primaryCompletion":3937,"completion":3937,"start":3938,"enrollment":942,"conditions":3962,"interventions":3963},[89],[3930],[3915,3941,3932],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"trials":3969,"activeCount":99},[],{"intervention":917,"totalTrials":380,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3973,"activeCount":99},[],{"trials":3975,"activeCount":99},[],{"trials":3977,"activeCount":99},[3978,3982],{"nctId":908,"briefTitle":909,"status":153,"phases":3979,"primaryCompletion":157,"completion":911,"start":912,"conditions":3980,"interventions":3981},[89],[16],[915,916,917,139,140,918,142,141],{"nctId":3289,"briefTitle":3290,"status":153,"phases":3983,"primaryCompletion":157,"completion":911,"start":912,"conditions":3984,"interventions":3985},[89],[16],[915,916,917],{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[],{"trials":3991,"activeCount":99},[],{"intervention":3336,"totalTrials":380,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":4002,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3995,"activeCount":99},[],{"trials":3997,"activeCount":99},[3998],{"nctId":3311,"briefTitle":3312,"status":153,"phases":3999,"primaryCompletion":1183,"completion":1183,"start":3314,"enrollment":881,"conditions":4000,"interventions":4001},[88],[3316,3317,3318,1199,3319,3320,1174,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332,3333],[3335,3336,1244],{"trials":4003,"activeCount":99},[4004],{"nctId":3147,"briefTitle":3148,"status":153,"phases":4005,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":4006,"interventions":4007},[89],[16,3154],[945,1021,3156,171,172,3157],{"trials":4009,"activeCount":99},[],{"trials":4011,"activeCount":99},[],{"trials":4013,"activeCount":99},[],{"intervention":213,"totalTrials":380,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4024,"PHASE3":4030,"PHASE4":4032,"NA":4034},{"trials":4017,"activeCount":99},[],{"trials":4019,"activeCount":99},[4020],{"nctId":1316,"briefTitle":1317,"status":153,"phases":4021,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1171,"conditions":4022,"interventions":4023},[88],[1322,1323,1324,1325,1187],[969,213,1327,143,778],{"trials":4025,"activeCount":99},[4026],{"nctId":206,"briefTitle":207,"status":153,"phases":4027,"primaryCompletion":209,"completion":210,"start":179,"conditions":4028,"interventions":4029},[89],[16],[118,213,172,214],{"trials":4031,"activeCount":99},[],{"trials":4033,"activeCount":99},[],{"trials":4035,"activeCount":99},[],{"intervention":335,"totalTrials":380,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4039,"activeCount":99},[],{"trials":4041,"activeCount":99},[],{"trials":4043,"activeCount":99},[4044,4048],{"nctId":765,"briefTitle":766,"status":153,"phases":4045,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":4046,"interventions":4047},[89],[242,25,16,773,722,774,775],[332,335,139,330,331,777,778],{"nctId":216,"briefTitle":217,"status":126,"phases":4049,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":4050,"interventions":4051},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":4053,"activeCount":99},[],{"trials":4055,"activeCount":99},[],{"trials":4057,"activeCount":99},[],{"intervention":4059,"totalTrials":380,"cells":4060},"Bevacizumab",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4073,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[4065],{"nctId":4066,"briefTitle":4067,"status":126,"phases":4068,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":119,"conditions":4071,"interventions":4072},"NCT02833701","Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma",[88],"2019-03","2016-03",[1860,820],[4059],{"trials":4074,"activeCount":99},[4075],{"nctId":1011,"briefTitle":1012,"status":126,"phases":4076,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":4077,"interventions":4078},[89],[1017,1002,1004,1005,1006],[140,139,1019,886,1020,1021],{"trials":4080,"activeCount":99},[],{"trials":4082,"activeCount":99},[],{"trials":4084,"activeCount":99},[],{"intervention":4086,"totalTrials":380,"cells":4087},"Levonorgestrel",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4089,"activeCount":99},[],{"trials":4091,"activeCount":99},[],{"trials":4093,"activeCount":99},[4094,4107],{"nctId":4095,"briefTitle":4096,"status":153,"phases":4097,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":1416,"conditions":4101,"interventions":4104},"NCT01789879","A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy",[89],"2014-09-01","2015-03-04","2014-03-04",[4102,4103],"HIV","Contraception",[4086,4105,4106],"Nevirapine","Efavirenz",{"nctId":4108,"briefTitle":4109,"status":153,"phases":4110,"primaryCompletion":4111,"completion":4112,"start":4113,"enrollment":4114,"conditions":4115,"interventions":4116},"NCT02722421","Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women",[89],"2019-12-05","2020-03-30","2017-04-06",28,[4102,4103],[4086,4106],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[],{"trials":4122,"activeCount":99},[],{"intervention":4124,"totalTrials":380,"cells":4125},"Tocilizumab",{"EARLY_PHASE1":4126,"PHASE1":4128,"PHASE2":4130,"PHASE3":4155,"PHASE4":4157,"NA":4159},{"trials":4127,"activeCount":99},[],{"trials":4129,"activeCount":99},[],{"trials":4131,"activeCount":99},[4132,4142],{"nctId":4133,"briefTitle":4134,"status":716,"phases":4135,"primaryCompletion":4136,"completion":4136,"start":4137,"enrollment":99,"conditions":4138,"interventions":4140},"NCT02511067","Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study",[89],"2016-10-05","2016-10-01",[4139],"Diabetic Macular Edema",[4124,4141],"Ranibizumab",{"nctId":4143,"briefTitle":4144,"status":2027,"phases":4145,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4150,"interventions":4154},"NCT01717170","Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study",[88,89],"2017-06","2017-12","2013-03",36,[4151,4152,4153],"Intermediate Uveitis","Posterior Uveitis","Pan-uveitis",[4124],{"trials":4156,"activeCount":99},[],{"trials":4158,"activeCount":99},[],{"trials":4160,"activeCount":99},[],{"intervention":1021,"totalTrials":380,"cells":4162},{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4164,"activeCount":99},[],{"trials":4166,"activeCount":99},[],{"trials":4168,"activeCount":99},[4169,4173],{"nctId":3147,"briefTitle":3148,"status":153,"phases":4170,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":4171,"interventions":4172},[89],[16,3154],[945,1021,3156,171,172,3157],{"nctId":1011,"briefTitle":1012,"status":126,"phases":4174,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":862,"conditions":4175,"interventions":4176},[89],[1017,1002,1004,1005,1006],[140,139,1019,886,1020,1021],{"trials":4178,"activeCount":99},[],{"trials":4180,"activeCount":99},[],{"trials":4182,"activeCount":99},[],{"intervention":4184,"totalTrials":380,"cells":4185},"Placebos",{"EARLY_PHASE1":4186,"PHASE1":4198,"PHASE2":4200,"PHASE3":4214,"PHASE4":4216,"NA":4218},{"trials":4187,"activeCount":99},[4188],{"nctId":4189,"briefTitle":4190,"status":716,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":4192,"enrollment":99,"conditions":4193,"interventions":4195},"NCT03688464","Treatment of Nighttime Pruritus in Atopic Dermatitis",[87],"2019-02-02",[4194],"Atopic Dermatitis",[4196,4197,4184],"Melatonin","Diphenhydramine",{"trials":4199,"activeCount":99},[],{"trials":4201,"activeCount":99},[4202],{"nctId":4203,"briefTitle":4204,"status":153,"phases":4205,"primaryCompletion":4206,"completion":4206,"start":4207,"enrollment":23,"conditions":4208,"interventions":4212},"NCT04279392","Healthy Body, Healthy Bones After Bariatric Surgery Trial",[88,89],"2022-12-30","2020-09-01",[4209,4210,4211],"Bariatric Surgery Candidate","Bone Loss","Bone Resorption",[4213,4184],"Zoledronic Acid 5 mg\u002FBag 100 ml Inj",{"trials":4215,"activeCount":99},[],{"trials":4217,"activeCount":99},[],{"trials":4219,"activeCount":99},[],{"intervention":3279,"totalTrials":95,"cells":4221},{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4223,"activeCount":99},[],{"trials":4225,"activeCount":99},[],{"trials":4227,"activeCount":99},[4228],{"nctId":3271,"briefTitle":3272,"status":126,"phases":4229,"primaryCompletion":3274,"completion":3274,"start":3275,"enrollment":3276,"conditions":4230,"interventions":4231},[89],[16],[3279,915,916],{"trials":4233,"activeCount":99},[],{"trials":4235,"activeCount":99},[],{"trials":4237,"activeCount":99},[],{"intervention":3378,"totalTrials":95,"cells":4239},{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4244,"PHASE3":4250,"PHASE4":4252,"NA":4254},{"trials":4241,"activeCount":99},[],{"trials":4243,"activeCount":99},[],{"trials":4245,"activeCount":99},[4246],{"nctId":3370,"briefTitle":3371,"status":126,"phases":4247,"primaryCompletion":3373,"completion":3373,"start":3374,"enrollment":26,"conditions":4248,"interventions":4249},[89],[3376],[203,3378,3379],{"trials":4251,"activeCount":99},[],{"trials":4253,"activeCount":99},[],{"trials":4255,"activeCount":99},[],{"intervention":3379,"totalTrials":95,"cells":4257},{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4259,"activeCount":99},[],{"trials":4261,"activeCount":99},[],{"trials":4263,"activeCount":99},[4264],{"nctId":3370,"briefTitle":3371,"status":126,"phases":4265,"primaryCompletion":3373,"completion":3373,"start":3374,"enrollment":26,"conditions":4266,"interventions":4267},[89],[3376],[203,3378,3379],{"trials":4269,"activeCount":99},[],{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[],{"intervention":725,"totalTrials":95,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4277,"activeCount":99},[],{"trials":4279,"activeCount":99},[],{"trials":4281,"activeCount":99},[4282],{"nctId":714,"briefTitle":715,"status":716,"phases":4283,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":4284,"interventions":4285},[88,89],[721,25,16,722,723],[725,330,726,145,727,728],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[],{"intervention":727,"totalTrials":95,"cells":4293},{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4295,"activeCount":99},[],{"trials":4297,"activeCount":99},[],{"trials":4299,"activeCount":99},[4300],{"nctId":714,"briefTitle":715,"status":716,"phases":4301,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":4302,"interventions":4303},[88,89],[721,25,16,722,723],[725,330,726,145,727,728],{"trials":4305,"activeCount":99},[],{"trials":4307,"activeCount":99},[],{"trials":4309,"activeCount":99},[],{"intervention":728,"totalTrials":95,"cells":4311},{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4313,"activeCount":99},[],{"trials":4315,"activeCount":99},[],{"trials":4317,"activeCount":99},[4318],{"nctId":714,"briefTitle":715,"status":716,"phases":4319,"primaryCompletion":718,"completion":718,"start":719,"enrollment":99,"conditions":4320,"interventions":4321},[88,89],[721,25,16,722,723],[725,330,726,145,727,728],{"trials":4323,"activeCount":99},[],{"trials":4325,"activeCount":99},[],{"trials":4327,"activeCount":99},[],{"intervention":4329,"totalTrials":95,"cells":4330},"autologous dendritic cell-adenovirus p53 vaccine",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4345,"PHASE4":4347,"NA":4349},{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[4337],{"nctId":4338,"briefTitle":4339,"status":153,"phases":4340,"primaryCompletion":4341,"completion":3517,"start":4342,"enrollment":693,"conditions":4343,"interventions":4344},"NCT00082641","Neoadjuvant\u002FAdjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer",[88,89],"2009-05-01","2004-01-01",[19],[4329],{"trials":4346,"activeCount":99},[],{"trials":4348,"activeCount":99},[],{"trials":4350,"activeCount":99},[],{"intervention":4352,"totalTrials":95,"cells":4353},"Ruxolitinib Phosphate",{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4373,"PHASE4":4375,"NA":4377},{"trials":4355,"activeCount":99},[],{"trials":4357,"activeCount":99},[],{"trials":4359,"activeCount":99},[4360],{"nctId":4361,"briefTitle":4362,"status":153,"phases":4363,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4368,"interventions":4372},"NCT01431209","Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant",[89],"2020-10-28","2021-05-26","2011-08-12",71,[4369,195,4370,4371],"Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",[4352],{"trials":4374,"activeCount":99},[],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"intervention":3635,"totalTrials":95,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4382,"activeCount":99},[],{"trials":4384,"activeCount":99},[],{"trials":4386,"activeCount":99},[4387],{"nctId":3628,"briefTitle":3629,"status":126,"phases":4388,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":10,"conditions":4389,"interventions":4390},[89],[1937,1173],[3635,3636,3637,3638,1226],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[],{"intervention":3636,"totalTrials":95,"cells":4398},{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4400,"activeCount":99},[],{"trials":4402,"activeCount":99},[],{"trials":4404,"activeCount":99},[4405],{"nctId":3628,"briefTitle":3629,"status":126,"phases":4406,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":10,"conditions":4407,"interventions":4408},[89],[1937,1173],[3635,3636,3637,3638,1226],{"trials":4410,"activeCount":99},[],{"trials":4412,"activeCount":99},[],{"trials":4414,"activeCount":99},[],{"intervention":3637,"totalTrials":95,"cells":4416},{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4427,"PHASE4":4429,"NA":4431},{"trials":4418,"activeCount":99},[],{"trials":4420,"activeCount":99},[],{"trials":4422,"activeCount":99},[4423],{"nctId":3628,"briefTitle":3629,"status":126,"phases":4424,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":10,"conditions":4425,"interventions":4426},[89],[1937,1173],[3635,3636,3637,3638,1226],{"trials":4428,"activeCount":99},[],{"trials":4430,"activeCount":99},[],{"trials":4432,"activeCount":99},[],{"intervention":3638,"totalTrials":95,"cells":4434},{"EARLY_PHASE1":4435,"PHASE1":4437,"PHASE2":4439,"PHASE3":4445,"PHASE4":4447,"NA":4449},{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[4441],{"nctId":3628,"briefTitle":3629,"status":126,"phases":4442,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":10,"conditions":4443,"interventions":4444},[89],[1937,1173],[3635,3636,3637,3638,1226],{"trials":4446,"activeCount":99},[],{"trials":4448,"activeCount":99},[],{"trials":4450,"activeCount":99},[],{"intervention":4452,"totalTrials":95,"cells":4453},"Sildenafil citrate",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4470,"PHASE4":4472,"NA":4474},{"trials":4455,"activeCount":99},[],{"trials":4457,"activeCount":99},[],{"trials":4459,"activeCount":99},[4460],{"nctId":4461,"briefTitle":4462,"status":716,"phases":4463,"primaryCompletion":4464,"completion":4464,"start":4465,"enrollment":99,"conditions":4466,"interventions":4469},"NCT00871065","Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm",[89],"2009-02-25","2008-07",[4467,4468],"Cerebral Vasospasm","Subarachnoid Hemorrhage",[4452],{"trials":4471,"activeCount":99},[],{"trials":4473,"activeCount":99},[],{"trials":4475,"activeCount":99},[],{"intervention":884,"totalTrials":95,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4488,"PHASE4":4490,"NA":4492},{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[4484],{"nctId":875,"briefTitle":876,"status":153,"phases":4485,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":4486,"interventions":4487},[89],[19],[884,885,139,140,886,887,144,888,889],{"trials":4489,"activeCount":99},[],{"trials":4491,"activeCount":99},[],{"trials":4493,"activeCount":99},[],{"intervention":885,"totalTrials":95,"cells":4495},{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4497,"activeCount":99},[],{"trials":4499,"activeCount":99},[],{"trials":4501,"activeCount":99},[4502],{"nctId":875,"briefTitle":876,"status":153,"phases":4503,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":4504,"interventions":4505},[89],[19],[884,885,139,140,886,887,144,888,889],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"intervention":887,"totalTrials":95,"cells":4513},{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4524,"PHASE4":4526,"NA":4528},{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[4520],{"nctId":875,"briefTitle":876,"status":153,"phases":4521,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":4522,"interventions":4523},[89],[19],[884,885,139,140,886,887,144,888,889],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"trials":4529,"activeCount":99},[],{"intervention":4531,"totalTrials":95,"cells":4532},"Islets of Langerhans",{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4537,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4534,"activeCount":99},[],{"trials":4536,"activeCount":99},[],{"trials":4538,"activeCount":99},[4539],{"nctId":4540,"briefTitle":4541,"status":126,"phases":4542,"primaryCompletion":4543,"completion":4543,"start":4544,"enrollment":942,"conditions":4545,"interventions":4548},"NCT00579371","Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus",[88,89],"2011-03","2004-03-17",[4546,4547],"Islets of Langerhans Transplantation","Diabetes Mellitus, Type 1",[4531],{"trials":4550,"activeCount":99},[],{"trials":4552,"activeCount":99},[],{"trials":4554,"activeCount":99},[],{"intervention":918,"totalTrials":95,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4558,"activeCount":99},[],{"trials":4560,"activeCount":99},[],{"trials":4562,"activeCount":99},[4563],{"nctId":908,"briefTitle":909,"status":153,"phases":4564,"primaryCompletion":157,"completion":911,"start":912,"conditions":4565,"interventions":4566},[89],[16],[915,916,917,139,140,918,142,141],{"trials":4568,"activeCount":99},[],{"trials":4570,"activeCount":99},[],{"trials":4572,"activeCount":99},[],{"intervention":4574,"totalTrials":95,"cells":4575},"ADX-629",{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4591,"PHASE4":4593,"NA":4595},{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[],{"trials":4581,"activeCount":99},[4582],{"nctId":4583,"briefTitle":4584,"status":153,"phases":4585,"primaryCompletion":4586,"completion":4586,"start":4587,"enrollment":26,"conditions":4588,"interventions":4590},"NCT05443685","ADX-629 Therapy for Sjogren-Larsson Syndrome",[88,89],"2026-04-01","2023-01-02",[4589],"Sjogren-Larsson Syndrome",[4574],{"trials":4592,"activeCount":99},[],{"trials":4594,"activeCount":99},[],{"trials":4596,"activeCount":99},[],{"intervention":4598,"totalTrials":95,"cells":4599},"Dasatinib",{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4616,"PHASE4":4618,"NA":4620},{"trials":4601,"activeCount":99},[],{"trials":4603,"activeCount":99},[],{"trials":4605,"activeCount":99},[4606],{"nctId":4607,"briefTitle":4608,"status":153,"phases":4609,"primaryCompletion":2682,"completion":4610,"start":4611,"enrollment":4612,"conditions":4613,"interventions":4614},"NCT00550615","Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma",[88,89],"2017-12-01","2007-09-17",38,[3520],[4598,4615],"Dasatinib Maximum Tolerated Dose",{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"trials":4621,"activeCount":99},[],{"intervention":4615,"totalTrials":95,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[4630],{"nctId":4607,"briefTitle":4608,"status":153,"phases":4631,"primaryCompletion":2682,"completion":4610,"start":4611,"enrollment":4612,"conditions":4632,"interventions":4633},[88,89],[3520],[4598,4615],{"trials":4635,"activeCount":99},[],{"trials":4637,"activeCount":99},[],{"trials":4639,"activeCount":99},[],{"intervention":746,"totalTrials":95,"cells":4641},{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4643,"activeCount":99},[],{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[4648],{"nctId":730,"briefTitle":731,"status":153,"phases":4649,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":4650,"interventions":4651},[89],[737,738,739,740,722,32,741,742,743],[745,746,747,748],{"trials":4653,"activeCount":99},[],{"trials":4655,"activeCount":99},[],{"trials":4657,"activeCount":99},[],{"intervention":748,"totalTrials":95,"cells":4659},{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4661,"activeCount":99},[],{"trials":4663,"activeCount":99},[],{"trials":4665,"activeCount":99},[4666],{"nctId":730,"briefTitle":731,"status":153,"phases":4667,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":4668,"interventions":4669},[89],[737,738,739,740,722,32,741,742,743],[745,746,747,748],{"trials":4671,"activeCount":99},[],{"trials":4673,"activeCount":99},[],{"trials":4675,"activeCount":99},[],{"intervention":4677,"totalTrials":95,"cells":4678},"Ibrutinib",{"EARLY_PHASE1":4679,"PHASE1":4681,"PHASE2":4683,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4680,"activeCount":99},[],{"trials":4682,"activeCount":99},[],{"trials":4684,"activeCount":99},[4685],{"nctId":4686,"briefTitle":4687,"status":153,"phases":4688,"primaryCompletion":2607,"completion":2607,"start":4689,"enrollment":1335,"conditions":4690,"interventions":4691},"NCT02874404","TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[89],"2016-10-07",[4369,4370],[4677,4692],"PI3K-delta Inhibitor TGR-1202",{"trials":4694,"activeCount":99},[],{"trials":4696,"activeCount":99},[],{"trials":4698,"activeCount":99},[],{"intervention":4692,"totalTrials":95,"cells":4700},{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4702,"activeCount":99},[],{"trials":4704,"activeCount":99},[],{"trials":4706,"activeCount":99},[4707],{"nctId":4686,"briefTitle":4687,"status":153,"phases":4708,"primaryCompletion":2607,"completion":2607,"start":4689,"enrollment":1335,"conditions":4709,"interventions":4710},[89],[4369,4370],[4677,4692],{"trials":4712,"activeCount":99},[],{"trials":4714,"activeCount":99},[],{"trials":4716,"activeCount":99},[],{"intervention":4718,"totalTrials":95,"cells":4719},"Oxytocin",{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4737,"PHASE4":4739,"NA":4741},{"trials":4721,"activeCount":99},[],{"trials":4723,"activeCount":99},[],{"trials":4725,"activeCount":99},[4726],{"nctId":4727,"briefTitle":4728,"status":153,"phases":4729,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":4732,"conditions":4733,"interventions":4736},"NCT02824627","Oxytocin on Irritability\u002FEmotional Dysregulation of Disruptive Behavior and Mood Disorders",[89],"2021-08-10","2017-01-27",58,[4734,4735],"Mood Disorder","Disruptive Behavior Disorders",[4718],{"trials":4738,"activeCount":99},[],{"trials":4740,"activeCount":99},[],{"trials":4742,"activeCount":99},[],{"intervention":1227,"totalTrials":95,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4749,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[4751],{"nctId":1214,"briefTitle":1215,"status":126,"phases":4752,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":10,"conditions":4753,"interventions":4754},[89],[1220,1221,1222,1223],[1211,1225,1226,1227],{"trials":4756,"activeCount":99},[],{"trials":4758,"activeCount":99},[],{"trials":4760,"activeCount":99},[],{"intervention":4762,"totalTrials":95,"cells":4763},"600 mg ibuprofen three times daily for 48 weeks",{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4765,"activeCount":99},[],{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[4770],{"nctId":4771,"briefTitle":4772,"status":153,"phases":4773,"primaryCompletion":4774,"completion":4774,"start":4775,"enrollment":684,"conditions":4776,"interventions":4778},"NCT02006576","Prostaglandin Inhibition for Emphysema",[89],"2018-03-31","2014-01-01",[4777],"Emphysema",[4762],{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"trials":4784,"activeCount":99},[],{"intervention":214,"totalTrials":95,"cells":4786},{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[4793],{"nctId":206,"briefTitle":207,"status":153,"phases":4794,"primaryCompletion":209,"completion":210,"start":179,"conditions":4795,"interventions":4796},[89],[16],[118,213,172,214],{"trials":4798,"activeCount":99},[],{"trials":4800,"activeCount":99},[],{"trials":4802,"activeCount":99},[],{"intervention":3733,"totalTrials":95,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4809,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4806,"activeCount":99},[],{"trials":4808,"activeCount":99},[],{"trials":4810,"activeCount":99},[4811],{"nctId":3724,"briefTitle":3725,"status":153,"phases":4812,"primaryCompletion":3716,"completion":3716,"start":3727,"enrollment":3728,"conditions":4813,"interventions":4814},[88,89],[3730,3731],[3733,3706],{"trials":4816,"activeCount":99},[],{"trials":4818,"activeCount":99},[],{"trials":4820,"activeCount":99},[],{"intervention":1246,"totalTrials":95,"cells":4822},{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4824,"activeCount":99},[],{"trials":4826,"activeCount":99},[],{"trials":4828,"activeCount":99},[4829],{"nctId":1229,"briefTitle":1230,"status":153,"phases":4830,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":10,"conditions":4831,"interventions":4832},[89],[1199,1236,1237,1238,1239,1240,1241,1242,1174],[1211,1244,1225,1245,1246],{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"trials":4838,"activeCount":99},[],{"intervention":4840,"totalTrials":95,"cells":4841},"Sorafenib",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4843,"activeCount":99},[],{"trials":4845,"activeCount":99},[],{"trials":4847,"activeCount":99},[4848],{"nctId":4849,"briefTitle":4850,"status":126,"phases":4851,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":20,"conditions":4855,"interventions":4857},"NCT00496756","Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer",[89],"2009-10-31","2014-04-25","2007-03-01",[4856],"Kidney Cancer",[4840],{"trials":4859,"activeCount":99},[],{"trials":4861,"activeCount":99},[],{"trials":4863,"activeCount":99},[],{"intervention":1290,"totalTrials":95,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4876,"PHASE4":4878,"NA":4880},{"trials":4867,"activeCount":99},[],{"trials":4869,"activeCount":99},[],{"trials":4871,"activeCount":99},[4872],{"nctId":1281,"briefTitle":1282,"status":153,"phases":4873,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":222,"conditions":4874,"interventions":4875},[89],[1287,1288],[905,1290],{"trials":4877,"activeCount":99},[],{"trials":4879,"activeCount":99},[],{"trials":4881,"activeCount":99},[],{"intervention":4883,"totalTrials":95,"cells":4884},"Cholic Acid",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4901,"PHASE4":4903,"NA":4905},{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[],{"trials":4890,"activeCount":99},[4891],{"nctId":4892,"briefTitle":4893,"status":153,"phases":4894,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":2119,"conditions":4898,"interventions":4900},"NCT03720990","Smith-Lemli-Opitz Syndrome and Cholic Acid",[88,89],"2022-08-30","2023-09-30","2021-03-27",[4899],"Smith-Lemli-Opitz Syndrome",[4883],{"trials":4902,"activeCount":99},[],{"trials":4904,"activeCount":99},[],{"trials":4906,"activeCount":99},[],{"intervention":4908,"totalTrials":95,"cells":4909},"talabostat mesylate",{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4914,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4911,"activeCount":99},[],{"trials":4913,"activeCount":99},[],{"trials":4915,"activeCount":99},[4916],{"nctId":4917,"briefTitle":4918,"status":716,"phases":4919,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":99,"conditions":4922,"interventions":4923},"NCT00489710","Talabostat in Treating Patients With Metastatic Kidney Cancer",[89],"2007-05-30","2006-12",[4856],[4908,4924,4925],"enzyme inhibitor therapy","non-specific immune-modulator therapy",{"trials":4927,"activeCount":99},[],{"trials":4929,"activeCount":99},[],{"trials":4931,"activeCount":99},[],{"intervention":4924,"totalTrials":95,"cells":4933},{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4938,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4935,"activeCount":99},[],{"trials":4937,"activeCount":99},[],{"trials":4939,"activeCount":99},[4940],{"nctId":4917,"briefTitle":4918,"status":716,"phases":4941,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":99,"conditions":4942,"interventions":4943},[89],[4856],[4908,4924,4925],{"trials":4945,"activeCount":99},[],{"trials":4947,"activeCount":99},[],{"trials":4949,"activeCount":99},[],{"intervention":4925,"totalTrials":95,"cells":4951},{"EARLY_PHASE1":4952,"PHASE1":4954,"PHASE2":4956,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4953,"activeCount":99},[],{"trials":4955,"activeCount":99},[],{"trials":4957,"activeCount":99},[4958],{"nctId":4917,"briefTitle":4918,"status":716,"phases":4959,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":99,"conditions":4960,"interventions":4961},[89],[4856],[4908,4924,4925],{"trials":4963,"activeCount":99},[],{"trials":4965,"activeCount":99},[],{"trials":4967,"activeCount":99},[],{"intervention":4969,"totalTrials":95,"cells":4970},"Ruxolitinib",{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4975,"PHASE3":4988,"PHASE4":4990,"NA":4992},{"trials":4972,"activeCount":99},[],{"trials":4974,"activeCount":99},[],{"trials":4976,"activeCount":99},[4977],{"nctId":4978,"briefTitle":4979,"status":153,"phases":4980,"primaryCompletion":4981,"completion":4982,"start":4983,"enrollment":4984,"conditions":4985,"interventions":4987},"NCT03616184","Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids",[89],"2022-01-22","2023-06-12","2018-09-05",49,[4986],"Graft-versus-host-disease (GVHD)",[4969],{"trials":4989,"activeCount":99},[],{"trials":4991,"activeCount":99},[],{"trials":4993,"activeCount":99},[],{"intervention":4995,"totalTrials":95,"cells":4996},"Omegaven™",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":4998,"activeCount":99},[],{"trials":5000,"activeCount":99},[],{"trials":5002,"activeCount":99},[5003],{"nctId":5004,"briefTitle":5005,"status":153,"phases":5006,"primaryCompletion":5007,"completion":5007,"start":4341,"enrollment":5008,"conditions":5009,"interventions":5012},"NCT00826020","Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis",[89],"2017-10-06",72,[5010,5011],"Parenteral Nutrition Associated Liver Disease PNALD","Cholestasis",[4995],{"trials":5014,"activeCount":99},[],{"trials":5016,"activeCount":99},[],{"trials":5018,"activeCount":99},[],{"intervention":5020,"totalTrials":95,"cells":5021},"ONC201",{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5039,"PHASE4":5041,"NA":5043},{"trials":5023,"activeCount":99},[],{"trials":5025,"activeCount":99},[],{"trials":5027,"activeCount":99},[5028],{"nctId":5029,"briefTitle":5030,"status":716,"phases":5031,"primaryCompletion":5032,"completion":5032,"start":5033,"enrollment":99,"conditions":5034,"interventions":5038},"NCT06012929","A Study of ONC201 for Refractory Meningioma",[89],"2027-04","2026-12",[5035,5036,5037],"Meningioma","Refractory Meningioma","Relapsed Meningioma",[5020],{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[],{"intervention":5046,"totalTrials":95,"cells":5047},"Cabozantinib",{"EARLY_PHASE1":5048,"PHASE1":5050,"PHASE2":5052,"PHASE3":5064,"PHASE4":5066,"NA":5068},{"trials":5049,"activeCount":99},[],{"trials":5051,"activeCount":99},[],{"trials":5053,"activeCount":99},[5054],{"nctId":5055,"briefTitle":5056,"status":126,"phases":5057,"primaryCompletion":5058,"completion":5058,"start":5059,"enrollment":10,"conditions":5060,"interventions":5063},"NCT03201250","Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma",[88,89],"2021-04-12","2018-02-21",[32,5061,5062],"Refractory Multiple Myeloma","Relapsed\u002FRefractory Multiple Myeloma",[5046],{"trials":5065,"activeCount":99},[],{"trials":5067,"activeCount":99},[],{"trials":5069,"activeCount":99},[],{"intervention":4105,"totalTrials":95,"cells":5071},{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5082,"PHASE4":5084,"NA":5086},{"trials":5073,"activeCount":99},[],{"trials":5075,"activeCount":99},[],{"trials":5077,"activeCount":99},[5078],{"nctId":4095,"briefTitle":4096,"status":153,"phases":5079,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":1416,"conditions":5080,"interventions":5081},[89],[4102,4103],[4086,4105,4106],{"trials":5083,"activeCount":99},[],{"trials":5085,"activeCount":99},[],{"trials":5087,"activeCount":99},[],{"intervention":970,"totalTrials":95,"cells":5089},{"EARLY_PHASE1":5090,"PHASE1":5092,"PHASE2":5094,"PHASE3":5100,"PHASE4":5102,"NA":5104},{"trials":5091,"activeCount":99},[],{"trials":5093,"activeCount":99},[],{"trials":5095,"activeCount":99},[5096],{"nctId":961,"briefTitle":962,"status":126,"phases":5097,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":5098,"interventions":5099},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"trials":5101,"activeCount":99},[],{"trials":5103,"activeCount":99},[],{"trials":5105,"activeCount":99},[],{"intervention":984,"totalTrials":95,"cells":5107},{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5118,"PHASE4":5120,"NA":5122},{"trials":5109,"activeCount":99},[],{"trials":5111,"activeCount":99},[],{"trials":5113,"activeCount":99},[5114],{"nctId":973,"briefTitle":974,"status":153,"phases":5115,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":5116,"interventions":5117},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":5119,"activeCount":99},[],{"trials":5121,"activeCount":99},[],{"trials":5123,"activeCount":99},[],{"intervention":986,"totalTrials":95,"cells":5125},{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5130,"PHASE3":5136,"PHASE4":5138,"NA":5140},{"trials":5127,"activeCount":99},[],{"trials":5129,"activeCount":99},[],{"trials":5131,"activeCount":99},[5132],{"nctId":973,"briefTitle":974,"status":153,"phases":5133,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":5134,"interventions":5135},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":5137,"activeCount":99},[],{"trials":5139,"activeCount":99},[],{"trials":5141,"activeCount":99},[],{"intervention":989,"totalTrials":95,"cells":5143},{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5154,"PHASE4":5156,"NA":5158},{"trials":5145,"activeCount":99},[],{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[5150],{"nctId":973,"briefTitle":974,"status":153,"phases":5151,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":5152,"interventions":5153},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":5155,"activeCount":99},[],{"trials":5157,"activeCount":99},[],{"trials":5159,"activeCount":99},[],{"intervention":3743,"totalTrials":95,"cells":5161},{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5163,"activeCount":99},[],{"trials":5165,"activeCount":99},[],{"trials":5167,"activeCount":99},[5168],{"nctId":3735,"briefTitle":3736,"status":153,"phases":5169,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":1405,"conditions":5170,"interventions":5171},[88,89],[16],[3743,3706],{"trials":5173,"activeCount":99},[],{"trials":5175,"activeCount":99},[],{"trials":5177,"activeCount":99},[],{"intervention":4141,"totalTrials":95,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5184,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5181,"activeCount":99},[],{"trials":5183,"activeCount":99},[],{"trials":5185,"activeCount":99},[5186],{"nctId":4133,"briefTitle":4134,"status":716,"phases":5187,"primaryCompletion":4136,"completion":4136,"start":4137,"enrollment":99,"conditions":5188,"interventions":5189},[89],[4139],[4124,4141],{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[],{"trials":5195,"activeCount":99},[],{"intervention":3204,"totalTrials":95,"cells":5197},{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5208,"PHASE4":5210,"NA":5212},{"trials":5199,"activeCount":99},[],{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[5204],{"nctId":3197,"briefTitle":3198,"status":126,"phases":5205,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":380,"conditions":5206,"interventions":5207},[88,89],[722],[945,3204,171,143],{"trials":5209,"activeCount":99},[],{"trials":5211,"activeCount":99},[],{"trials":5213,"activeCount":99},[],{"intervention":3218,"totalTrials":95,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":99},[],{"trials":5219,"activeCount":99},[],{"trials":5221,"activeCount":99},[5222],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5223,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5224,"interventions":5225},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5227,"activeCount":99},[],{"trials":5229,"activeCount":99},[],{"trials":5231,"activeCount":99},[],{"intervention":3219,"totalTrials":95,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5244,"PHASE4":5246,"NA":5248},{"trials":5235,"activeCount":99},[],{"trials":5237,"activeCount":99},[],{"trials":5239,"activeCount":99},[5240],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5241,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5242,"interventions":5243},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5245,"activeCount":99},[],{"trials":5247,"activeCount":99},[],{"trials":5249,"activeCount":99},[],{"intervention":3220,"totalTrials":95,"cells":5251},{"EARLY_PHASE1":5252,"PHASE1":5254,"PHASE2":5256,"PHASE3":5262,"PHASE4":5264,"NA":5266},{"trials":5253,"activeCount":99},[],{"trials":5255,"activeCount":99},[],{"trials":5257,"activeCount":99},[5258],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5259,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5260,"interventions":5261},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5263,"activeCount":99},[],{"trials":5265,"activeCount":99},[],{"trials":5267,"activeCount":99},[],{"intervention":3221,"totalTrials":95,"cells":5269},{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5274,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5271,"activeCount":99},[],{"trials":5273,"activeCount":99},[],{"trials":5275,"activeCount":99},[5276],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5277,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5278,"interventions":5279},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5281,"activeCount":99},[],{"trials":5283,"activeCount":99},[],{"trials":5285,"activeCount":99},[],{"intervention":3222,"totalTrials":95,"cells":5287},{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[],{"trials":5293,"activeCount":99},[5294],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5295,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5296,"interventions":5297},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5299,"activeCount":99},[],{"trials":5301,"activeCount":99},[],{"trials":5303,"activeCount":99},[],{"intervention":3223,"totalTrials":95,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":99},[],{"trials":5309,"activeCount":99},[],{"trials":5311,"activeCount":99},[5312],{"nctId":3206,"briefTitle":3207,"status":153,"phases":5313,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":5314,"interventions":5315},[89],[3214,3215,3216],[200,3218,3219,3220,3221,3222,3223],{"trials":5317,"activeCount":99},[],{"trials":5319,"activeCount":99},[],{"trials":5321,"activeCount":99},[],{"intervention":3157,"totalTrials":95,"cells":5323},{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5325,"activeCount":99},[],{"trials":5327,"activeCount":99},[],{"trials":5329,"activeCount":99},[5330],{"nctId":3147,"briefTitle":3148,"status":153,"phases":5331,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":1416,"conditions":5332,"interventions":5333},[89],[16,3154],[945,1021,3156,171,172,3157],{"trials":5335,"activeCount":99},[],{"trials":5337,"activeCount":99},[],{"trials":5339,"activeCount":99},[],{"intervention":3522,"totalTrials":95,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":99},[],{"trials":5345,"activeCount":99},[],{"trials":5347,"activeCount":99},[5348],{"nctId":3513,"briefTitle":3514,"status":153,"phases":5349,"primaryCompletion":3516,"completion":3517,"start":3518,"enrollment":1171,"conditions":5350,"interventions":5351},[88,89],[3520],[202,3522],{"trials":5353,"activeCount":99},[],{"trials":5355,"activeCount":99},[],{"trials":5357,"activeCount":99},[],{"intervention":1420,"totalTrials":95,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5361,"activeCount":99},[],{"trials":5363,"activeCount":99},[],{"trials":5365,"activeCount":99},[5366],{"nctId":1411,"briefTitle":1412,"status":126,"phases":5367,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":5368,"interventions":5369},[88,89],[1418],[1420,1421,1422,1423],{"trials":5371,"activeCount":99},[],{"trials":5373,"activeCount":99},[],{"trials":5375,"activeCount":99},[],{"intervention":1422,"totalTrials":95,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5380,"PHASE2":5382,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5379,"activeCount":99},[],{"trials":5381,"activeCount":99},[],{"trials":5383,"activeCount":99},[5384],{"nctId":1411,"briefTitle":1412,"status":126,"phases":5385,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":5386,"interventions":5387},[88,89],[1418],[1420,1421,1422,1423],{"trials":5389,"activeCount":99},[],{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"intervention":1423,"totalTrials":95,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5400,"PHASE3":5406,"PHASE4":5408,"NA":5410},{"trials":5397,"activeCount":99},[],{"trials":5399,"activeCount":99},[],{"trials":5401,"activeCount":99},[5402],{"nctId":1411,"briefTitle":1412,"status":126,"phases":5403,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":5404,"interventions":5405},[88,89],[1418],[1420,1421,1422,1423],{"trials":5407,"activeCount":99},[],{"trials":5409,"activeCount":99},[],{"trials":5411,"activeCount":99},[],{"intervention":3941,"totalTrials":95,"cells":5413},{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5418,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5415,"activeCount":99},[],{"trials":5417,"activeCount":99},[],{"trials":5419,"activeCount":99},[5420],{"nctId":3934,"briefTitle":3935,"status":153,"phases":5421,"primaryCompletion":3937,"completion":3937,"start":3938,"enrollment":942,"conditions":5422,"interventions":5423},[89],[3930],[3915,3941,3932],{"trials":5425,"activeCount":99},[],{"trials":5427,"activeCount":99},[],{"trials":5429,"activeCount":99},[],{"intervention":4213,"totalTrials":95,"cells":5431},{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5433,"activeCount":99},[],{"trials":5435,"activeCount":99},[],{"trials":5437,"activeCount":99},[5438],{"nctId":4203,"briefTitle":4204,"status":153,"phases":5439,"primaryCompletion":4206,"completion":4206,"start":4207,"enrollment":23,"conditions":5440,"interventions":5441},[88,89],[4209,4210,4211],[4213,4184],{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":99},[],{"trials":5447,"activeCount":99},[],{"intervention":5449,"totalTrials":95,"cells":5450},"Gefitinib plus etoposide",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5455,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5452,"activeCount":99},[],{"trials":5454,"activeCount":99},[],{"trials":5456,"activeCount":99},[5457],{"nctId":5458,"briefTitle":5459,"status":126,"phases":5460,"primaryCompletion":5461,"completion":5461,"start":5462,"enrollment":158,"conditions":5463,"interventions":5464},"NCT00483561","Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy",[89],"2010-01","2004-01",[34],[5449],{"trials":5466,"activeCount":99},[],{"trials":5468,"activeCount":99},[],{"trials":5470,"activeCount":99},[],{"intervention":5472,"totalTrials":95,"cells":5473},"Evolocumab",{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5478,"PHASE3":5489,"PHASE4":5491,"NA":5493},{"trials":5475,"activeCount":99},[],{"trials":5477,"activeCount":99},[],{"trials":5479,"activeCount":99},[5480],{"nctId":5481,"briefTitle":5482,"status":153,"phases":5483,"primaryCompletion":5484,"completion":5484,"start":5485,"enrollment":158,"conditions":5486,"interventions":5488},"NCT03944577","Impact of Evolocumab in Cardiac Transplant Patients With CAV",[89],"2023-03-28","2019-07-15",[5487],"Heart Transplant",[5472],{"trials":5490,"activeCount":99},[],{"trials":5492,"activeCount":99},[],{"trials":5494,"activeCount":99},[],{"intervention":333,"totalTrials":95,"cells":5496},{"EARLY_PHASE1":5497,"PHASE1":5499,"PHASE2":5501,"PHASE3":5507,"PHASE4":5509,"NA":5511},{"trials":5498,"activeCount":99},[],{"trials":5500,"activeCount":99},[],{"trials":5502,"activeCount":99},[5503],{"nctId":216,"briefTitle":217,"status":126,"phases":5504,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":5505,"interventions":5506},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":5508,"activeCount":99},[],{"trials":5510,"activeCount":99},[],{"trials":5512,"activeCount":99},[],{"intervention":334,"totalTrials":95,"cells":5514},{"EARLY_PHASE1":5515,"PHASE1":5517,"PHASE2":5519,"PHASE3":5525,"PHASE4":5527,"NA":5529},{"trials":5516,"activeCount":99},[],{"trials":5518,"activeCount":99},[],{"trials":5520,"activeCount":99},[5521],{"nctId":216,"briefTitle":217,"status":126,"phases":5522,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":5523,"interventions":5524},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":5526,"activeCount":99},[],{"trials":5528,"activeCount":99},[],{"trials":5530,"activeCount":99},[],{"intervention":336,"totalTrials":95,"cells":5532},{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5543,"PHASE4":5545,"NA":5547},{"trials":5534,"activeCount":99},[],{"trials":5536,"activeCount":99},[],{"trials":5538,"activeCount":99},[5539],{"nctId":216,"briefTitle":217,"status":126,"phases":5540,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":5541,"interventions":5542},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":5544,"activeCount":99},[],{"trials":5546,"activeCount":99},[],{"trials":5548,"activeCount":99},[],{"intervention":337,"totalTrials":95,"cells":5550},{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5561,"PHASE4":5563,"NA":5565},{"trials":5552,"activeCount":99},[],{"trials":5554,"activeCount":99},[],{"trials":5556,"activeCount":99},[5557],{"nctId":216,"briefTitle":217,"status":126,"phases":5558,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":5559,"interventions":5560},[89],[224,225,226,227,228,229,132,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,133,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,194,270,271,272,273,274,275,276,277,134,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,135,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,136,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328],[118,330,331,332,333,139,334,335,336,337],{"trials":5562,"activeCount":99},[],{"trials":5564,"activeCount":99},[],{"trials":5566,"activeCount":99},[],{"intervention":5568,"totalTrials":380,"cells":5569},"Bicalutamide",{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5588,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5571,"activeCount":99},[],{"trials":5573,"activeCount":99},[5574,5584],{"nctId":5575,"briefTitle":5576,"status":716,"phases":5577,"primaryCompletion":5578,"completion":5578,"start":5579,"enrollment":99,"conditions":5580,"interventions":5583},"NCT06501911","A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent\u002FProgressive High Grade Glioma",[88],"2025-07-17","2025-04-08",[5581,5582],"Recurrent Glioblastoma","Recurrent High-grade Glioma",[5568],{"nctId":3757,"briefTitle":3758,"status":153,"phases":5585,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":119,"conditions":5586,"interventions":5587},[88],[34],[3764,971,3765],{"trials":5589,"activeCount":99},[],{"trials":5591,"activeCount":99},[],{"trials":5593,"activeCount":99},[],{"trials":5595,"activeCount":99},[],{"intervention":5597,"totalTrials":95,"cells":5598},"Aflibercept",{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5612,"PHASE3":5614,"PHASE4":5616,"NA":5618},{"trials":5600,"activeCount":99},[],{"trials":5602,"activeCount":99},[5603],{"nctId":5604,"briefTitle":5605,"status":153,"phases":5606,"primaryCompletion":5607,"completion":5607,"start":5608,"enrollment":771,"conditions":5609,"interventions":5611},"NCT02204683","Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration",[88],"2016-12-14","2014-09-05",[5610],"Neovascular Macular Degeneration",[5597],{"trials":5613,"activeCount":99},[],{"trials":5615,"activeCount":99},[],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[],{"intervention":1189,"totalTrials":95,"cells":5621},{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5630,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5623,"activeCount":99},[],{"trials":5625,"activeCount":99},[5626],{"nctId":1179,"briefTitle":1180,"status":153,"phases":5627,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":5628,"interventions":5629},[88],[1187],[985,1158,1189,777,987,778],{"trials":5631,"activeCount":99},[],{"trials":5633,"activeCount":99},[],{"trials":5635,"activeCount":99},[],{"trials":5637,"activeCount":99},[],{"intervention":5639,"totalTrials":95,"cells":5640},"Donor Enriched Activated Natural Killer Cell",{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5652,"PHASE3":5654,"PHASE4":5656,"NA":5658},{"trials":5642,"activeCount":99},[],{"trials":5644,"activeCount":99},[5645],{"nctId":5646,"briefTitle":5647,"status":716,"phases":5648,"primaryCompletion":5649,"completion":5649,"start":5649,"enrollment":99,"conditions":5650,"interventions":5651},"NCT05375253","Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies",[88],"2023-04-12",[25],[5639],{"trials":5653,"activeCount":99},[],{"trials":5655,"activeCount":99},[],{"trials":5657,"activeCount":99},[],{"trials":5659,"activeCount":99},[],{"intervention":5661,"totalTrials":95,"cells":5662},"Stellate Ganglion Block",{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5677,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5664,"activeCount":99},[],{"trials":5666,"activeCount":99},[5667],{"nctId":5668,"briefTitle":5669,"status":126,"phases":5670,"primaryCompletion":2630,"completion":5671,"start":5672,"enrollment":95,"conditions":5673,"interventions":5676},"NCT04445337","Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients",[88],"2021-11-01","2020-11-15",[5674,5675],"COVID 19","ARDS",[5661],{"trials":5678,"activeCount":99},[],{"trials":5680,"activeCount":99},[],{"trials":5682,"activeCount":99},[],{"trials":5684,"activeCount":99},[],{"intervention":5686,"totalTrials":95,"cells":5687},"carfilzomib",{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[5692],{"nctId":5693,"briefTitle":5694,"status":153,"phases":5695,"primaryCompletion":5696,"completion":5697,"start":5698,"enrollment":862,"conditions":5699,"interventions":5700},"NCT01336920","Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma",[88],"2015-04-01","2018-03-01","2011-06-21",[227,980,981,743,265],[5686],{"trials":5702,"activeCount":99},[],{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"trials":5708,"activeCount":99},[],{"intervention":1075,"totalTrials":95,"cells":5710},{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5719,"PHASE3":5721,"PHASE4":5723,"NA":5725},{"trials":5712,"activeCount":99},[],{"trials":5714,"activeCount":99},[5715],{"nctId":1066,"briefTitle":1067,"status":153,"phases":5716,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":5717,"interventions":5718},[88],[1073],[1009,1075],{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[],{"trials":5726,"activeCount":99},[],{"intervention":5728,"totalTrials":95,"cells":5729},"Tenofovir Disoproxil Fumarate\u002FEmtricitabine",{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5743,"PHASE3":5745,"PHASE4":5747,"NA":5749},{"trials":5731,"activeCount":99},[],{"trials":5733,"activeCount":99},[5734],{"nctId":5735,"briefTitle":5736,"status":153,"phases":5737,"primaryCompletion":5738,"completion":5738,"start":5739,"enrollment":862,"conditions":5740,"interventions":5742},"NCT03270969","A Pharmacokinetic Evaluation of Tenofovir\u002FEmtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women",[88],"2018-09-10","2018-01-05",[5741],"HIV Prevention",[5728],{"trials":5744,"activeCount":99},[],{"trials":5746,"activeCount":99},[],{"trials":5748,"activeCount":99},[],{"trials":5750,"activeCount":99},[],{"intervention":3335,"totalTrials":95,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5761,"PHASE3":5763,"PHASE4":5765,"NA":5767},{"trials":5754,"activeCount":99},[],{"trials":5756,"activeCount":99},[5757],{"nctId":3311,"briefTitle":3312,"status":153,"phases":5758,"primaryCompletion":1183,"completion":1183,"start":3314,"enrollment":881,"conditions":5759,"interventions":5760},[88],[3316,3317,3318,1199,3319,3320,1174,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332,3333],[3335,3336,1244],{"trials":5762,"activeCount":99},[],{"trials":5764,"activeCount":99},[],{"trials":5766,"activeCount":99},[],{"trials":5768,"activeCount":99},[],{"intervention":5770,"totalTrials":95,"cells":5771},"Regadenoson",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5785,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5773,"activeCount":99},[],{"trials":5775,"activeCount":99},[5776],{"nctId":5777,"briefTitle":5778,"status":153,"phases":5779,"primaryCompletion":5780,"completion":5781,"start":5782,"enrollment":1670,"conditions":5783,"interventions":5784},"NCT00837369","Regadenoson R-T Perfusion Imaging Trial",[88],"2011-03-01","2011-12-01","2009-04-07",[3080,3081],[5770],{"trials":5786,"activeCount":99},[],{"trials":5788,"activeCount":99},[],{"trials":5790,"activeCount":99},[],{"trials":5792,"activeCount":99},[],{"intervention":5794,"totalTrials":95,"cells":5795},"CYR-064",{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5809,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5797,"activeCount":99},[],{"trials":5799,"activeCount":99},[5800],{"nctId":5801,"briefTitle":5802,"status":716,"phases":5803,"primaryCompletion":65,"completion":1716,"start":5804,"enrollment":99,"conditions":5805,"interventions":5808},"NCT06498687","Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia",[88],"2025-04",[5806,5807],"Hyposmia","Anosmia",[5794],{"trials":5810,"activeCount":99},[],{"trials":5812,"activeCount":99},[],{"trials":5814,"activeCount":99},[],{"trials":5816,"activeCount":99},[],{"intervention":1327,"totalTrials":95,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5827,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5820,"activeCount":99},[],{"trials":5822,"activeCount":99},[5823],{"nctId":1316,"briefTitle":1317,"status":153,"phases":5824,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1171,"conditions":5825,"interventions":5826},[88],[1322,1323,1324,1325,1187],[969,213,1327,143,778],{"trials":5828,"activeCount":99},[],{"trials":5830,"activeCount":99},[],{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[],{"intervention":5836,"totalTrials":95,"cells":5837},"stool softener",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5859},{"trials":5839,"activeCount":99},[],{"trials":5841,"activeCount":99},[5842],{"nctId":5843,"briefTitle":5844,"status":153,"phases":5845,"primaryCompletion":5846,"completion":5847,"start":5848,"enrollment":5849,"conditions":5850,"interventions":5852},"NCT01156129","Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery",[88],"2012-07-01","2012-12-01","2010-09-01",111,[5851],"Ileus",[5836],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"trials":5858,"activeCount":99},[],{"trials":5860,"activeCount":99},[],{"intervention":5862,"totalTrials":95,"cells":5863},"ONC-201",{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5877,"PHASE3":5879,"PHASE4":5881,"NA":5883},{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":99},[5868],{"nctId":5869,"briefTitle":5870,"status":153,"phases":5871,"primaryCompletion":5872,"completion":5872,"start":5873,"enrollment":222,"conditions":5874,"interventions":5876},"NCT03932643","ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant",[88],"2025-03-27","2019-07-30",[5875,722],"Acute Myeloid Leukemia",[5862],{"trials":5878,"activeCount":99},[],{"trials":5880,"activeCount":99},[],{"trials":5882,"activeCount":99},[],{"trials":5884,"activeCount":99},[],{"intervention":5886,"totalTrials":95,"cells":5887},"Inhaled, nebulized, Milrinone",{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5904,"PHASE3":5906,"PHASE4":5908,"NA":5910},{"trials":5889,"activeCount":99},[],{"trials":5891,"activeCount":99},[5892],{"nctId":5893,"briefTitle":5894,"status":153,"phases":5895,"primaryCompletion":5896,"completion":5897,"start":5898,"enrollment":23,"conditions":5899,"interventions":5902},"NCT01571037","Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study",[88],"2013-02-01","2014-02-21","2012-04-05",[5900,5901],"End Stage Heart Disease","Right Ventricular Dysfunction",[5886,5903],"inhaled nebulized milrinone",{"trials":5905,"activeCount":99},[],{"trials":5907,"activeCount":99},[],{"trials":5909,"activeCount":99},[],{"trials":5911,"activeCount":99},[],{"intervention":5903,"totalTrials":95,"cells":5913},{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5922,"PHASE3":5924,"PHASE4":5926,"NA":5928},{"trials":5915,"activeCount":99},[],{"trials":5917,"activeCount":99},[5918],{"nctId":5893,"briefTitle":5894,"status":153,"phases":5919,"primaryCompletion":5896,"completion":5897,"start":5898,"enrollment":23,"conditions":5920,"interventions":5921},[88],[5900,5901],[5886,5903],{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[],{"intervention":5931,"totalTrials":95,"cells":5932},"M-TOR Immunosuppression",{"EARLY_PHASE1":5933,"PHASE1":5935,"PHASE2":5947,"PHASE3":5949,"PHASE4":5951,"NA":5953},{"trials":5934,"activeCount":99},[],{"trials":5936,"activeCount":99},[5937],{"nctId":5938,"briefTitle":5939,"status":126,"phases":5940,"primaryCompletion":5941,"completion":5941,"start":5942,"enrollment":3728,"conditions":5943,"interventions":5945},"NCT01889992","Cardiac Allograft Remodeling and Effects of Sirolimus",[88],"2018-09-27","2013-04-24",[5944,2034],"Cardiac Hypertrophy",[5931,5946],"Genetic Mechanism of M-TOR",{"trials":5948,"activeCount":99},[],{"trials":5950,"activeCount":99},[],{"trials":5952,"activeCount":99},[],{"trials":5954,"activeCount":99},[],{"intervention":5946,"totalTrials":95,"cells":5956},{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5965,"PHASE3":5967,"PHASE4":5969,"NA":5971},{"trials":5958,"activeCount":99},[],{"trials":5960,"activeCount":99},[5961],{"nctId":5938,"briefTitle":5939,"status":126,"phases":5962,"primaryCompletion":5941,"completion":5941,"start":5942,"enrollment":3728,"conditions":5963,"interventions":5964},[88],[5944,2034],[5931,5946],{"trials":5966,"activeCount":99},[],{"trials":5968,"activeCount":99},[],{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[],{"intervention":5974,"totalTrials":95,"cells":5975},"Durvalumab + Tremelimumab in combination with carboplatin and etoposide",{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":5996},{"trials":5977,"activeCount":99},[],{"trials":5979,"activeCount":99},[5980],{"nctId":5981,"briefTitle":5982,"status":126,"phases":5983,"primaryCompletion":5984,"completion":5984,"start":5985,"enrollment":95,"conditions":5986,"interventions":5988},"NCT03963414","A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC",[88],"2021-12-15","2020-09-25",[5987],"Small Cell Lung Carcinoma",[5974,5989],"Durvalumab in combination with carboplatin and etoposide",{"trials":5991,"activeCount":99},[],{"trials":5993,"activeCount":99},[],{"trials":5995,"activeCount":99},[],{"trials":5997,"activeCount":99},[],{"intervention":5989,"totalTrials":95,"cells":5999},{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":6001,"activeCount":99},[],{"trials":6003,"activeCount":99},[6004],{"nctId":5981,"briefTitle":5982,"status":126,"phases":6005,"primaryCompletion":5984,"completion":5984,"start":5985,"enrollment":95,"conditions":6006,"interventions":6007},[88],[5987],[5974,5989],{"trials":6009,"activeCount":99},[],{"trials":6011,"activeCount":99},[],{"trials":6013,"activeCount":99},[],{"trials":6015,"activeCount":99},[],{"intervention":3765,"totalTrials":95,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6026,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":6019,"activeCount":99},[],{"trials":6021,"activeCount":99},[6022],{"nctId":3757,"briefTitle":3758,"status":153,"phases":6023,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":119,"conditions":6024,"interventions":6025},[88],[34],[3764,971,3765],{"trials":6027,"activeCount":99},[],{"trials":6029,"activeCount":99},[],{"trials":6031,"activeCount":99},[],{"trials":6033,"activeCount":99},[],{"intervention":1338,"totalTrials":95,"cells":6035},{"EARLY_PHASE1":6036,"PHASE1":6038,"PHASE2":6044,"PHASE3":6046,"PHASE4":6048,"NA":6050},{"trials":6037,"activeCount":99},[],{"trials":6039,"activeCount":99},[6040],{"nctId":1329,"briefTitle":1330,"status":153,"phases":6041,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":6042,"interventions":6043},[88],[1187],[969,1020,1338,988,987,777],{"trials":6045,"activeCount":99},[],{"trials":6047,"activeCount":99},[],{"trials":6049,"activeCount":99},[],{"trials":6051,"activeCount":99},[],{"intervention":6053,"totalTrials":95,"cells":6054},"Two-Layer Method pancreas preservation system drug",{"EARLY_PHASE1":6055,"PHASE1":6066,"PHASE2":6068,"PHASE3":6070,"PHASE4":6072,"NA":6074},{"trials":6056,"activeCount":99},[6057],{"nctId":6058,"briefTitle":6059,"status":126,"phases":6060,"primaryCompletion":6061,"completion":6061,"start":6062,"enrollment":35,"conditions":6063,"interventions":6065},"NCT00592280","Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation",[87],"2009-04","2007-10",[6064],"Graft Pancreatitis",[6053],{"trials":6067,"activeCount":99},[],{"trials":6069,"activeCount":99},[],{"trials":6071,"activeCount":99},[],{"trials":6073,"activeCount":99},[],{"trials":6075,"activeCount":99},[],{"intervention":6077,"totalTrials":95,"cells":6078},"Betaine",{"EARLY_PHASE1":6079,"PHASE1":6093,"PHASE2":6095,"PHASE3":6097,"PHASE4":6099,"NA":6101},{"trials":6080,"activeCount":99},[6081],{"nctId":6082,"briefTitle":6083,"status":126,"phases":6084,"primaryCompletion":6085,"completion":6085,"start":4341,"enrollment":380,"conditions":6086,"interventions":6090},"NCT00882193","Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder\u002FRelapsers",[87],"2011-01-12",[6087,6088,6089],"Chronic Hepatitis C","Genotype 1","Relapse",[6077,6091,6092],"Peginterferon alpha 2a","Ribavirin",{"trials":6094,"activeCount":99},[],{"trials":6096,"activeCount":99},[],{"trials":6098,"activeCount":99},[],{"trials":6100,"activeCount":99},[],{"trials":6102,"activeCount":99},[],{"intervention":6091,"totalTrials":95,"cells":6104},{"EARLY_PHASE1":6105,"PHASE1":6111,"PHASE2":6113,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6106,"activeCount":99},[6107],{"nctId":6082,"briefTitle":6083,"status":126,"phases":6108,"primaryCompletion":6085,"completion":6085,"start":4341,"enrollment":380,"conditions":6109,"interventions":6110},[87],[6087,6088,6089],[6077,6091,6092],{"trials":6112,"activeCount":99},[],{"trials":6114,"activeCount":99},[],{"trials":6116,"activeCount":99},[],{"trials":6118,"activeCount":99},[],{"trials":6120,"activeCount":99},[],{"intervention":6092,"totalTrials":95,"cells":6122},{"EARLY_PHASE1":6123,"PHASE1":6129,"PHASE2":6131,"PHASE3":6133,"PHASE4":6135,"NA":6137},{"trials":6124,"activeCount":99},[6125],{"nctId":6082,"briefTitle":6083,"status":126,"phases":6126,"primaryCompletion":6085,"completion":6085,"start":4341,"enrollment":380,"conditions":6127,"interventions":6128},[87],[6087,6088,6089],[6077,6091,6092],{"trials":6130,"activeCount":99},[],{"trials":6132,"activeCount":99},[],{"trials":6134,"activeCount":99},[],{"trials":6136,"activeCount":99},[],{"trials":6138,"activeCount":99},[],{"intervention":6140,"totalTrials":95,"cells":6141},"Ibuprofen 600Mg",{"EARLY_PHASE1":6142,"PHASE1":6154,"PHASE2":6156,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6143,"activeCount":99},[6144],{"nctId":6145,"briefTitle":6146,"status":126,"phases":6147,"primaryCompletion":6148,"completion":6148,"start":6149,"enrollment":23,"conditions":6150,"interventions":6153},"NCT03822962","Pain Management Following Sinus Surgery",[87],"2023-05-30","2020-11-07",[6151,6152,2311],"Nasal Sinus; Inflammation","Opioid Abuse",[6140],{"trials":6155,"activeCount":99},[],{"trials":6157,"activeCount":99},[],{"trials":6159,"activeCount":99},[],{"trials":6161,"activeCount":99},[],{"trials":6163,"activeCount":99},[],{"intervention":138,"totalTrials":95,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6172,"PHASE2":6174,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":99},[6168],{"nctId":124,"briefTitle":125,"status":126,"phases":6169,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":6170,"interventions":6171},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":6173,"activeCount":99},[],{"trials":6175,"activeCount":99},[],{"trials":6177,"activeCount":99},[],{"trials":6179,"activeCount":99},[],{"trials":6181,"activeCount":99},[],{"intervention":6183,"totalTrials":95,"cells":6184},"Hyaluronidase",{"EARLY_PHASE1":6185,"PHASE1":6197,"PHASE2":6199,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6186,"activeCount":99},[6187],{"nctId":6188,"briefTitle":6189,"status":153,"phases":6190,"primaryCompletion":6191,"completion":6191,"start":6192,"enrollment":966,"conditions":6193,"interventions":6196},"NCT05995626","Hyaluronidase Via LADD Scleroderma-induced Microstomia",[87],"2024-09-24","2024-03-01",[6194,6195],"Microstomia","Scleroderma",[6183],{"trials":6198,"activeCount":99},[],{"trials":6200,"activeCount":99},[],{"trials":6202,"activeCount":99},[],{"trials":6204,"activeCount":99},[],{"trials":6206,"activeCount":99},[],{"intervention":6208,"totalTrials":95,"cells":6209},"Enamel Matrix Proteins Derivative",{"EARLY_PHASE1":6210,"PHASE1":6221,"PHASE2":6223,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6211,"activeCount":99},[6212],{"nctId":6213,"briefTitle":6214,"status":153,"phases":6215,"primaryCompletion":6216,"completion":6216,"start":6217,"enrollment":2284,"conditions":6218,"interventions":6220},"NCT02972788","Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients",[87],"2018-09-20","2017-02-01",[6219],"Periodontal Bone Loss",[6208],{"trials":6222,"activeCount":99},[],{"trials":6224,"activeCount":99},[],{"trials":6226,"activeCount":99},[],{"trials":6228,"activeCount":99},[],{"trials":6230,"activeCount":99},[],{"intervention":6232,"totalTrials":95,"cells":6233},"Brimonidine",{"EARLY_PHASE1":6234,"PHASE1":6247,"PHASE2":6249,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6235,"activeCount":99},[6236],{"nctId":6237,"briefTitle":6238,"status":153,"phases":6239,"primaryCompletion":6240,"completion":6240,"start":6241,"enrollment":6242,"conditions":6243,"interventions":6245},"NCT01144494","Aqueous Humor Dynamics and Brimonidine",[87],"2011-10-01","2010-08-01",35,[6244],"Intraocular Pressure",[6232,6246],"Artificial tears",{"trials":6248,"activeCount":99},[],{"trials":6250,"activeCount":99},[],{"trials":6252,"activeCount":99},[],{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[],{"intervention":6246,"totalTrials":95,"cells":6258},{"EARLY_PHASE1":6259,"PHASE1":6265,"PHASE2":6267,"PHASE3":6269,"PHASE4":6271,"NA":6273},{"trials":6260,"activeCount":99},[6261],{"nctId":6237,"briefTitle":6238,"status":153,"phases":6262,"primaryCompletion":6240,"completion":6240,"start":6241,"enrollment":6242,"conditions":6263,"interventions":6264},[87],[6244],[6232,6246],{"trials":6266,"activeCount":99},[],{"trials":6268,"activeCount":99},[],{"trials":6270,"activeCount":99},[],{"trials":6272,"activeCount":99},[],{"trials":6274,"activeCount":99},[],{"intervention":4196,"totalTrials":95,"cells":6276},{"EARLY_PHASE1":6277,"PHASE1":6283,"PHASE2":6285,"PHASE3":6287,"PHASE4":6289,"NA":6291},{"trials":6278,"activeCount":99},[6279],{"nctId":4189,"briefTitle":4190,"status":716,"phases":6280,"primaryCompletion":4192,"completion":4192,"start":4192,"enrollment":99,"conditions":6281,"interventions":6282},[87],[4194],[4196,4197,4184],{"trials":6284,"activeCount":99},[],{"trials":6286,"activeCount":99},[],{"trials":6288,"activeCount":99},[],{"trials":6290,"activeCount":99},[],{"trials":6292,"activeCount":99},[],{"intervention":4197,"totalTrials":95,"cells":6294},{"EARLY_PHASE1":6295,"PHASE1":6301,"PHASE2":6303,"PHASE3":6305,"PHASE4":6307,"NA":6309},{"trials":6296,"activeCount":99},[6297],{"nctId":4189,"briefTitle":4190,"status":716,"phases":6298,"primaryCompletion":4192,"completion":4192,"start":4192,"enrollment":99,"conditions":6299,"interventions":6300},[87],[4194],[4196,4197,4184],{"trials":6302,"activeCount":99},[],{"trials":6304,"activeCount":99},[],{"trials":6306,"activeCount":99},[],{"trials":6308,"activeCount":99},[],{"trials":6310,"activeCount":99},[],{"intervention":144,"totalTrials":771,"cells":6312},{"EARLY_PHASE1":6313,"PHASE1":6319,"PHASE2":6321,"PHASE3":6335,"PHASE4":6337,"NA":6339},{"trials":6314,"activeCount":99},[6315],{"nctId":124,"briefTitle":125,"status":126,"phases":6316,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":6317,"interventions":6318},[87],[132,133,134,135,136],[138,118,139,140,141,142,143,144,145],{"trials":6320,"activeCount":99},[],{"trials":6322,"activeCount":99},[6323,6327,6331],{"nctId":875,"briefTitle":876,"status":153,"phases":6324,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":6325,"interventions":6326},[89],[19],[884,885,139,140,886,887,144,888,889],{"nctId":961,"briefTitle":962,"status":126,"phases":6328,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":6329,"interventions":6330},[89],[19],[945,969,970,139,971,140,144,778,888,889],{"nctId":973,"briefTitle":974,"status":153,"phases":6332,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":6333,"interventions":6334},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":6336,"activeCount":99},[],{"trials":6338,"activeCount":99},[],{"trials":6340,"activeCount":99},[6341],{"nctId":6342,"briefTitle":6343,"status":153,"phases":6344,"primaryCompletion":6345,"completion":6346,"start":6347,"enrollment":862,"conditions":6348,"interventions":6350},"NCT00617799","Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma",[],"2009-02-18","2010-04-16","2007-10-02",[4856,6349],"Melanoma (Skin)",[6351,144,988],"aldesleukin",{"intervention":4106,"totalTrials":966,"cells":6353},{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6358,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6355,"activeCount":99},[],{"trials":6357,"activeCount":99},[],{"trials":6359,"activeCount":99},[6360,6364],{"nctId":4095,"briefTitle":4096,"status":153,"phases":6361,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":1416,"conditions":6362,"interventions":6363},[89],[4102,4103],[4086,4105,4106],{"nctId":4108,"briefTitle":4109,"status":153,"phases":6365,"primaryCompletion":4111,"completion":4112,"start":4113,"enrollment":4114,"conditions":6366,"interventions":6367},[89],[4102,4103],[4086,4106],{"trials":6369,"activeCount":99},[],{"trials":6371,"activeCount":99},[],{"trials":6373,"activeCount":99},[6374],{"nctId":6375,"briefTitle":6376,"status":153,"phases":6377,"primaryCompletion":6378,"completion":1284,"start":6379,"enrollment":942,"conditions":6380,"interventions":6382},"NCT01886404","EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients",[],"2014-05-01","2013-12-01",[6381],"HIV Infection",[4106],{"intervention":988,"totalTrials":966,"cells":6384},{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6393,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6386,"activeCount":99},[],{"trials":6388,"activeCount":99},[6389],{"nctId":1329,"briefTitle":1330,"status":153,"phases":6390,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":6391,"interventions":6392},[88],[1187],[969,1020,1338,988,987,777],{"trials":6394,"activeCount":99},[6395],{"nctId":973,"briefTitle":974,"status":153,"phases":6396,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":6397,"interventions":6398},[89],[980,981,982,743],[142,139,172,984,985,986,144,987,988,143,989],{"trials":6400,"activeCount":99},[],{"trials":6402,"activeCount":99},[],{"trials":6404,"activeCount":99},[6405],{"nctId":6342,"briefTitle":6343,"status":153,"phases":6406,"primaryCompletion":6345,"completion":6346,"start":6347,"enrollment":862,"conditions":6407,"interventions":6408},[],[4856,6349],[6351,144,988],{"intervention":6410,"totalTrials":380,"cells":6411},"cannabidiol",{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6425,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6413,"activeCount":99},[],{"trials":6415,"activeCount":99},[6416],{"nctId":6417,"briefTitle":6418,"status":716,"phases":6419,"primaryCompletion":6420,"completion":6420,"start":6420,"enrollment":99,"conditions":6421,"interventions":6424},"NCT05646459","Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.",[88],"2020-05-14",[6422,6423],"Periodontitis, Adult","Inflammation Gum",[6410],{"trials":6426,"activeCount":99},[],{"trials":6428,"activeCount":99},[],{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[6433],{"nctId":6434,"briefTitle":6435,"status":6436,"phases":6437,"conditions":6438,"interventions":6440},"NCT02660255","Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy","APPROVED_FOR_MARKETING",[],[6439],"Epilepsy",[6441],"Cannabidiol",{"intervention":6443,"totalTrials":380,"cells":6444},"Sodium Bicarbonate",{"EARLY_PHASE1":6445,"PHASE1":6447,"PHASE2":6449,"PHASE3":6451,"PHASE4":6453,"NA":6459},{"trials":6446,"activeCount":99},[],{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":99},[],{"trials":6454,"activeCount":99},[6455],{"nctId":2795,"briefTitle":2796,"status":126,"phases":6456,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":112,"conditions":6457,"interventions":6458},[91],[2801],[2782,2803],{"trials":6460,"activeCount":99},[6461],{"nctId":6462,"briefTitle":6463,"status":126,"phases":6464,"primaryCompletion":6465,"completion":6465,"start":6466,"enrollment":6467,"conditions":6468,"interventions":6470},"NCT00579995","A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate",[92],"2010-04-08","2005-05-01",41,[6469],"Nephropathy",[6471,6443],"Oral N-Acetylcysteine",{"intervention":6473,"totalTrials":380,"cells":6474},"nicotine polacrilex",{"EARLY_PHASE1":6475,"PHASE1":6477,"PHASE2":6479,"PHASE3":6481,"PHASE4":6483,"NA":6485},{"trials":6476,"activeCount":99},[],{"trials":6478,"activeCount":99},[],{"trials":6480,"activeCount":99},[],{"trials":6482,"activeCount":99},[],{"trials":6484,"activeCount":99},[],{"trials":6486,"activeCount":99},[6487,6498],{"nctId":6488,"briefTitle":6489,"status":153,"phases":6490,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":1416,"conditions":6493,"interventions":6495},"NCT00468234","Validation of Biomarkers of Exposure and Host Response",[92],"2007-09","2005-12",[6494],"Cigarette Smoker",[6473,6496,6497],"nicotine transdermal system","nicotine inhaler",{"nctId":6499,"briefTitle":6500,"status":126,"phases":6501,"primaryCompletion":6502,"completion":6502,"start":6503,"enrollment":6242,"conditions":6504,"interventions":6506},"NCT00482690","Analysis of Aldehyde Biomarkers of Exposure and Host Response",[92],"2007-09-09","2005-08-23",[6505],"Smoking Cessation",[6473,6496,6497],{"intervention":6496,"totalTrials":380,"cells":6508},{"EARLY_PHASE1":6509,"PHASE1":6511,"PHASE2":6513,"PHASE3":6515,"PHASE4":6517,"NA":6519},{"trials":6510,"activeCount":99},[],{"trials":6512,"activeCount":99},[],{"trials":6514,"activeCount":99},[],{"trials":6516,"activeCount":99},[],{"trials":6518,"activeCount":99},[],{"trials":6520,"activeCount":99},[6521,6525],{"nctId":6488,"briefTitle":6489,"status":153,"phases":6522,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":1416,"conditions":6523,"interventions":6524},[92],[6494],[6473,6496,6497],{"nctId":6499,"briefTitle":6500,"status":126,"phases":6526,"primaryCompletion":6502,"completion":6502,"start":6503,"enrollment":6242,"conditions":6527,"interventions":6528},[92],[6505],[6473,6496,6497],{"intervention":6497,"totalTrials":380,"cells":6530},{"EARLY_PHASE1":6531,"PHASE1":6533,"PHASE2":6535,"PHASE3":6537,"PHASE4":6539,"NA":6541},{"trials":6532,"activeCount":99},[],{"trials":6534,"activeCount":99},[],{"trials":6536,"activeCount":99},[],{"trials":6538,"activeCount":99},[],{"trials":6540,"activeCount":99},[],{"trials":6542,"activeCount":99},[6543,6547],{"nctId":6488,"briefTitle":6489,"status":153,"phases":6544,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":1416,"conditions":6545,"interventions":6546},[92],[6494],[6473,6496,6497],{"nctId":6499,"briefTitle":6500,"status":126,"phases":6548,"primaryCompletion":6502,"completion":6502,"start":6503,"enrollment":6242,"conditions":6549,"interventions":6550},[92],[6505],[6473,6496,6497],{"intervention":6552,"totalTrials":95,"cells":6553},"Raltegravir",{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6558,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6555,"activeCount":99},[],{"trials":6557,"activeCount":99},[],{"trials":6559,"activeCount":99},[],{"trials":6561,"activeCount":99},[],{"trials":6563,"activeCount":99},[],{"trials":6565,"activeCount":99},[6566],{"nctId":6567,"briefTitle":6568,"status":153,"phases":6569,"primaryCompletion":6570,"completion":6571,"start":2392,"enrollment":2119,"conditions":6572,"interventions":6573},"NCT01214486","Measurement of Plasma and Intracellular Concentrations of Raltegravir",[92],"2011-04-30","2011-06-30",[4102],[6552],{"intervention":6575,"totalTrials":95,"cells":6576},"autologous platelet gel",{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6583,"PHASE4":6585,"NA":6587},{"trials":6578,"activeCount":99},[],{"trials":6580,"activeCount":99},[],{"trials":6582,"activeCount":99},[],{"trials":6584,"activeCount":99},[],{"trials":6586,"activeCount":99},[],{"trials":6588,"activeCount":99},[6589],{"nctId":6590,"briefTitle":6591,"status":716,"phases":6592,"primaryCompletion":6593,"completion":6593,"start":6594,"enrollment":99,"conditions":6595,"interventions":6598},"NCT00672672","Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients",[92],"2010-01-06","2009-01-13",[6596,6597],"Wounds","Infection",[6575],{"intervention":6600,"totalTrials":95,"cells":6601},"nicotine polacrilex, transdermal system or inhaler",{"EARLY_PHASE1":6602,"PHASE1":6604,"PHASE2":6606,"PHASE3":6608,"PHASE4":6610,"NA":6612},{"trials":6603,"activeCount":99},[],{"trials":6605,"activeCount":99},[],{"trials":6607,"activeCount":99},[],{"trials":6609,"activeCount":99},[],{"trials":6611,"activeCount":99},[],{"trials":6613,"activeCount":99},[6614],{"nctId":6615,"briefTitle":6616,"status":126,"phases":6617,"primaryCompletion":6502,"completion":6502,"start":6503,"enrollment":693,"conditions":6618,"interventions":6620},"NCT00493831","Analysis of Lipid Biomarkers of Exposure and Host Response",[92],[6619],"Cigarette Smoking",[6600],{"intervention":6622,"totalTrials":95,"cells":6623},"Citalopram",{"EARLY_PHASE1":6624,"PHASE1":6626,"PHASE2":6628,"PHASE3":6630,"PHASE4":6632,"NA":6634},{"trials":6625,"activeCount":99},[],{"trials":6627,"activeCount":99},[],{"trials":6629,"activeCount":99},[],{"trials":6631,"activeCount":99},[],{"trials":6633,"activeCount":99},[],{"trials":6635,"activeCount":99},[6636],{"nctId":6637,"briefTitle":6638,"status":716,"phases":6639,"primaryCompletion":6640,"completion":6640,"start":2772,"enrollment":99,"conditions":6641,"interventions":6642},"NCT00876226","Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome",[92],"2012-09-11",[2659],[6622],{"intervention":6644,"totalTrials":95,"cells":6645},"Optison",{"EARLY_PHASE1":6646,"PHASE1":6648,"PHASE2":6650,"PHASE3":6652,"PHASE4":6654,"NA":6656},{"trials":6647,"activeCount":99},[],{"trials":6649,"activeCount":99},[],{"trials":6651,"activeCount":99},[],{"trials":6653,"activeCount":99},[],{"trials":6655,"activeCount":99},[],{"trials":6657,"activeCount":99},[6658],{"nctId":6659,"briefTitle":6660,"status":716,"phases":6661,"primaryCompletion":4148,"completion":6662,"start":6663,"enrollment":99,"conditions":6664,"interventions":6668},"NCT00580580","Detection of Coronary Stenosis With Intravenous Microbubbles",[92],"2014-03","2012-02",[6665,6666,6667],"Coronary Stenosis","Carotid Stenosis","Myocardial Reperfusion",[6644,6669,6670],"Definity","PESDA",{"intervention":6669,"totalTrials":95,"cells":6672},{"EARLY_PHASE1":6673,"PHASE1":6675,"PHASE2":6677,"PHASE3":6679,"PHASE4":6681,"NA":6683},{"trials":6674,"activeCount":99},[],{"trials":6676,"activeCount":99},[],{"trials":6678,"activeCount":99},[],{"trials":6680,"activeCount":99},[],{"trials":6682,"activeCount":99},[],{"trials":6684,"activeCount":99},[6685],{"nctId":6659,"briefTitle":6660,"status":716,"phases":6686,"primaryCompletion":4148,"completion":6662,"start":6663,"enrollment":99,"conditions":6687,"interventions":6688},[92],[6665,6666,6667],[6644,6669,6670],{"intervention":6670,"totalTrials":95,"cells":6690},{"EARLY_PHASE1":6691,"PHASE1":6693,"PHASE2":6695,"PHASE3":6697,"PHASE4":6699,"NA":6701},{"trials":6692,"activeCount":99},[],{"trials":6694,"activeCount":99},[],{"trials":6696,"activeCount":99},[],{"trials":6698,"activeCount":99},[],{"trials":6700,"activeCount":99},[],{"trials":6702,"activeCount":99},[6703],{"nctId":6659,"briefTitle":6660,"status":716,"phases":6704,"primaryCompletion":4148,"completion":6662,"start":6663,"enrollment":99,"conditions":6705,"interventions":6706},[92],[6665,6666,6667],[6644,6669,6670],{"intervention":6471,"totalTrials":95,"cells":6708},{"EARLY_PHASE1":6709,"PHASE1":6711,"PHASE2":6713,"PHASE3":6715,"PHASE4":6717,"NA":6719},{"trials":6710,"activeCount":99},[],{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"trials":6718,"activeCount":99},[],{"trials":6720,"activeCount":99},[6721],{"nctId":6462,"briefTitle":6463,"status":126,"phases":6722,"primaryCompletion":6465,"completion":6465,"start":6466,"enrollment":6467,"conditions":6723,"interventions":6724},[92],[6469],[6471,6443],{"intervention":6726,"totalTrials":95,"cells":6727},"bupropion SR",{"EARLY_PHASE1":6728,"PHASE1":6730,"PHASE2":6732,"PHASE3":6734,"PHASE4":6736,"NA":6738},{"trials":6729,"activeCount":99},[],{"trials":6731,"activeCount":99},[],{"trials":6733,"activeCount":99},[],{"trials":6735,"activeCount":99},[],{"trials":6737,"activeCount":99},[],{"trials":6739,"activeCount":99},[6740],{"nctId":6741,"briefTitle":6742,"status":153,"phases":6743,"primaryCompletion":6744,"completion":6745,"start":6746,"enrollment":1781,"conditions":6747,"interventions":6749},"NCT00572234","Bupropion in the Treatment of Methamphetamine Dependence",[92],"2010-04-06","2011-05-20","2007-08-31",[6748],"Methamphetamine Use Disorder",[6726],{"intervention":6351,"totalTrials":95,"cells":6751},{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6756,"PHASE3":6758,"PHASE4":6760,"NA":6762},{"trials":6753,"activeCount":99},[],{"trials":6755,"activeCount":99},[],{"trials":6757,"activeCount":99},[],{"trials":6759,"activeCount":99},[],{"trials":6761,"activeCount":99},[],{"trials":6763,"activeCount":99},[6764],{"nctId":6342,"briefTitle":6343,"status":153,"phases":6765,"primaryCompletion":6345,"completion":6346,"start":6347,"enrollment":862,"conditions":6766,"interventions":6767},[],[4856,6349],[6351,144,988],{"intervention":6769,"totalTrials":95,"cells":6770},"High Dose Vitamin D3",{"EARLY_PHASE1":6771,"PHASE1":6773,"PHASE2":6775,"PHASE3":6777,"PHASE4":6779,"NA":6781},{"trials":6772,"activeCount":99},[],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"trials":6778,"activeCount":99},[],{"trials":6780,"activeCount":99},[],{"trials":6782,"activeCount":99},[6783],{"nctId":6784,"briefTitle":6785,"status":153,"phases":6786,"primaryCompletion":3264,"completion":3264,"start":6787,"enrollment":3728,"conditions":6788,"interventions":6793},"NCT01371877","The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment",[92],"2011-11-01",[6789,6790,6791,6792],"Urticaria","Angioedema","Hives","Swelling",[6769,6794],"Low Dose Vitamin D3",{"intervention":6794,"totalTrials":95,"cells":6796},{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6803,"PHASE4":6805,"NA":6807},{"trials":6798,"activeCount":99},[],{"trials":6800,"activeCount":99},[],{"trials":6802,"activeCount":99},[],{"trials":6804,"activeCount":99},[],{"trials":6806,"activeCount":99},[],{"trials":6808,"activeCount":99},[6809],{"nctId":6784,"briefTitle":6785,"status":153,"phases":6810,"primaryCompletion":3264,"completion":3264,"start":6787,"enrollment":3728,"conditions":6811,"interventions":6812},[92],[6789,6790,6791,6792],[6769,6794],{"intervention":6814,"totalTrials":95,"cells":6815},"Ethanol Lock",{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6820,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6817,"activeCount":99},[],{"trials":6819,"activeCount":99},[],{"trials":6821,"activeCount":99},[],{"trials":6823,"activeCount":99},[],{"trials":6825,"activeCount":99},[],{"trials":6827,"activeCount":99},[6828],{"nctId":6829,"briefTitle":6830,"status":716,"phases":6831,"primaryCompletion":6832,"completion":6832,"start":6833,"enrollment":99,"conditions":6834,"interventions":6836},"NCT01409772","Evaluation of 70% Ethanol Lock Solution to Prevent Catheter Related Blood Stream Infections in Pediatric Patients",[],"2009-07-09","2009-05",[6835,2659],"Blood Stream Infections",[6814],{"intervention":6838,"totalTrials":95,"cells":6839},"Id-KLH",{"EARLY_PHASE1":6840,"PHASE1":6842,"PHASE2":6844,"PHASE3":6846,"PHASE4":6848,"NA":6850},{"trials":6841,"activeCount":99},[],{"trials":6843,"activeCount":99},[],{"trials":6845,"activeCount":99},[],{"trials":6847,"activeCount":99},[],{"trials":6849,"activeCount":99},[],{"trials":6851,"activeCount":99},[6852],{"nctId":6853,"briefTitle":6854,"status":153,"phases":6855,"primaryCompletion":6856,"completion":6857,"start":6858,"enrollment":380,"conditions":6859,"interventions":6860},"NCT00574886","Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction Chemotherapy",[92],"2002-03-01","2008-04-15","2000-08-03",[16],[6838],{"intervention":6862,"totalTrials":95,"cells":6863},"Anti-HIV Agents",{"EARLY_PHASE1":6864,"PHASE1":6866,"PHASE2":6868,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6865,"activeCount":99},[],{"trials":6867,"activeCount":99},[],{"trials":6869,"activeCount":99},[],{"trials":6871,"activeCount":99},[],{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":99},[6876],{"nctId":6877,"briefTitle":6878,"status":716,"phases":6879,"primaryCompletion":6880,"completion":6880,"start":6881,"enrollment":99,"conditions":6882,"interventions":6883},"NCT02707926","The Lymphoid Tissue Pharmacology of Antiretroviral Drugs",[],"2023-08-17","2023-03-25",[6381],[6862],{"intervention":6885,"totalTrials":95,"cells":6886},"Omegaven",{"EARLY_PHASE1":6887,"PHASE1":6889,"PHASE2":6891,"PHASE3":6893,"PHASE4":6895,"NA":6897},{"trials":6888,"activeCount":99},[],{"trials":6890,"activeCount":99},[],{"trials":6892,"activeCount":99},[],{"trials":6894,"activeCount":99},[],{"trials":6896,"activeCount":99},[],{"trials":6898,"activeCount":99},[6899],{"nctId":6900,"briefTitle":6901,"status":6436,"phases":6902,"conditions":6903,"interventions":6905},"NCT02328768","Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children",[],[6904],"Total Parenteral Nutrition-Induced Cholestasis",[6885],{"intervention":6907,"totalTrials":95,"cells":6908},"aprepitant",{"EARLY_PHASE1":6909,"PHASE1":6911,"PHASE2":6913,"PHASE3":6915,"PHASE4":6917,"NA":6919},{"trials":6910,"activeCount":99},[],{"trials":6912,"activeCount":99},[],{"trials":6914,"activeCount":99},[],{"trials":6916,"activeCount":99},[],{"trials":6918,"activeCount":99},[],{"trials":6920,"activeCount":99},[6921],{"nctId":6922,"briefTitle":6923,"status":716,"phases":6924,"primaryCompletion":6925,"completion":6925,"start":6925,"enrollment":99,"conditions":6926,"interventions":6927},"NCT01186029","Comparison of Adding EMEND to PONV\u002FPDNV Treatment Regimen",[92],"2011-09-01",[2312],[6907],{"intervention":6929,"totalTrials":95,"cells":6930},"Epidural",{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6935,"PHASE3":6937,"PHASE4":6939,"NA":6941},{"trials":6932,"activeCount":99},[],{"trials":6934,"activeCount":99},[],{"trials":6936,"activeCount":99},[],{"trials":6938,"activeCount":99},[],{"trials":6940,"activeCount":99},[],{"trials":6942,"activeCount":99},[6943],{"nctId":6944,"briefTitle":6945,"status":153,"phases":6946,"primaryCompletion":2527,"completion":2527,"start":6947,"enrollment":5008,"conditions":6948,"interventions":6952},"NCT01848951","Comparison of Epidural and TAP Block in Abdominal Surgery",[],"2014-02-01",[6949,6950,6951],"Acute Pain","Surgery","Regional Anesthesia",[6929,6953],"TAP Block",{"intervention":6953,"totalTrials":95,"cells":6955},{"EARLY_PHASE1":6956,"PHASE1":6958,"PHASE2":6960,"PHASE3":6962,"PHASE4":6964,"NA":6966},{"trials":6957,"activeCount":99},[],{"trials":6959,"activeCount":99},[],{"trials":6961,"activeCount":99},[],{"trials":6963,"activeCount":99},[],{"trials":6965,"activeCount":99},[],{"trials":6967,"activeCount":99},[6968],{"nctId":6944,"briefTitle":6945,"status":153,"phases":6969,"primaryCompletion":2527,"completion":2527,"start":6947,"enrollment":5008,"conditions":6970,"interventions":6971},[],[6949,6950,6951],[6929,6953],{"intervention":6973,"totalTrials":95,"cells":6974},"Rosuvastatin",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6981,"PHASE4":6983,"NA":6985},{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[],{"trials":6980,"activeCount":99},[],{"trials":6982,"activeCount":99},[],{"trials":6984,"activeCount":99},[],{"trials":6986,"activeCount":99},[6987],{"nctId":6988,"briefTitle":6989,"status":153,"phases":6990,"primaryCompletion":6925,"completion":6925,"start":6991,"enrollment":222,"conditions":6992,"interventions":6994},"NCT00874757","Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects",[],"2010-11-15",[6993],"Healthy",[6973],{"intervention":6996,"totalTrials":95,"cells":6997},"Microbubbles",{"EARLY_PHASE1":6998,"PHASE1":7000,"PHASE2":7002,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6999,"activeCount":99},[],{"trials":7001,"activeCount":99},[],{"trials":7003,"activeCount":99},[],{"trials":7005,"activeCount":99},[],{"trials":7007,"activeCount":99},[],{"trials":7009,"activeCount":99},[7010],{"nctId":7011,"briefTitle":7012,"status":153,"phases":7013,"primaryCompletion":7014,"completion":7015,"start":7016,"enrollment":2284,"conditions":7017,"interventions":7020},"NCT02170103","Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial",[92],"2023-03-03","2023-09-03","2018-09-16",[7018,7019],"STEMI","Chest Pain",[6996],{"intervention":7022,"totalTrials":95,"cells":7023},"atorvastatin calcium",{"EARLY_PHASE1":7024,"PHASE1":7026,"PHASE2":7028,"PHASE3":7030,"PHASE4":7032,"NA":7034},{"trials":7025,"activeCount":99},[],{"trials":7027,"activeCount":99},[],{"trials":7029,"activeCount":99},[],{"trials":7031,"activeCount":99},[],{"trials":7033,"activeCount":99},[],{"trials":7035,"activeCount":99},[7036],{"nctId":7037,"briefTitle":7038,"status":716,"phases":7039,"primaryCompletion":7040,"completion":7040,"start":7041,"enrollment":99,"conditions":7042,"interventions":7048},"NCT01555632","Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy",[92],"2013-02","2012-03",[929,7043,7044,7045,7046,7047],"Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer","Stage IV Prostate Cancer",[7022],{"intervention":7050,"totalTrials":95,"cells":7051},"CHOP\u002FRituximab",{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7058,"PHASE4":7060,"NA":7062},{"trials":7053,"activeCount":99},[],{"trials":7055,"activeCount":99},[],{"trials":7057,"activeCount":99},[],{"trials":7059,"activeCount":99},[],{"trials":7061,"activeCount":99},[],{"trials":7063,"activeCount":99},[7064],{"nctId":7065,"briefTitle":7066,"status":153,"phases":7067,"primaryCompletion":7068,"completion":7069,"start":7070,"enrollment":2309,"conditions":7071,"interventions":7072},"NCT00574730","CHOP\u002FRituximab Followed by Maintenance PEG Intron in Treatment of Indolent\u002FFollicular Non-Hodgkin's Lymphoma",[92],"2005-08-01","2012-06-07","2001-05-23",[741],[7050,7073],"PEG INTRON",{"intervention":7073,"totalTrials":95,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7080,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7077,"activeCount":99},[],{"trials":7079,"activeCount":99},[],{"trials":7081,"activeCount":99},[],{"trials":7083,"activeCount":99},[],{"trials":7085,"activeCount":99},[],{"trials":7087,"activeCount":99},[7088],{"nctId":7065,"briefTitle":7066,"status":153,"phases":7089,"primaryCompletion":7068,"completion":7069,"start":7070,"enrollment":2309,"conditions":7090,"interventions":7091},[92],[741],[7050,7073],{"intervention":1841,"totalTrials":95,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7098,"PHASE3":7100,"PHASE4":7102,"NA":7104},{"trials":7095,"activeCount":99},[],{"trials":7097,"activeCount":99},[],{"trials":7099,"activeCount":99},[],{"trials":7101,"activeCount":99},[],{"trials":7103,"activeCount":99},[],{"trials":7105,"activeCount":99},[7106],{"nctId":1832,"briefTitle":1833,"status":153,"phases":7107,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1837,"conditions":7108,"interventions":7109},[92],[1839],[1212,1841,1842],{"intervention":1842,"totalTrials":95,"cells":7111},{"EARLY_PHASE1":7112,"PHASE1":7114,"PHASE2":7116,"PHASE3":7118,"PHASE4":7120,"NA":7122},{"trials":7113,"activeCount":99},[],{"trials":7115,"activeCount":99},[],{"trials":7117,"activeCount":99},[],{"trials":7119,"activeCount":99},[],{"trials":7121,"activeCount":99},[],{"trials":7123,"activeCount":99},[7124],{"nctId":1832,"briefTitle":1833,"status":153,"phases":7125,"primaryCompletion":1835,"completion":1835,"start":1836,"enrollment":1837,"conditions":7126,"interventions":7127},[92],[1839],[1212,1841,1842],{"intervention":7129,"totalTrials":95,"cells":7130},"Peginterferon alpha-2a and ribavirin",{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7135,"PHASE3":7137,"PHASE4":7139,"NA":7141},{"trials":7132,"activeCount":99},[],{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[],{"trials":7140,"activeCount":99},[],{"trials":7142,"activeCount":99},[7143],{"nctId":7144,"briefTitle":7145,"status":716,"phases":7146,"primaryCompletion":924,"completion":924,"start":7147,"enrollment":99,"conditions":7148,"interventions":7149},"NCT00571714","Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients",[92],"2008-04-01",[6087],[7129,7150],"Peginterferon alpha-2a , ribavirin and betaine",{"intervention":7150,"totalTrials":95,"cells":7152},{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7154,"activeCount":99},[],{"trials":7156,"activeCount":99},[],{"trials":7158,"activeCount":99},[],{"trials":7160,"activeCount":99},[],{"trials":7162,"activeCount":99},[],{"trials":7164,"activeCount":99},[7165],{"nctId":7144,"briefTitle":7145,"status":716,"phases":7166,"primaryCompletion":924,"completion":924,"start":7147,"enrollment":99,"conditions":7167,"interventions":7168},[92],[6087],[7129,7150],{"intervention":7170,"totalTrials":95,"cells":7171},"Drug\u002FSupplement only",{"EARLY_PHASE1":7172,"PHASE1":7174,"PHASE2":7176,"PHASE3":7178,"PHASE4":7180,"NA":7182},{"trials":7173,"activeCount":99},[],{"trials":7175,"activeCount":99},[],{"trials":7177,"activeCount":99},[],{"trials":7179,"activeCount":99},[],{"trials":7181,"activeCount":99},[],{"trials":7183,"activeCount":99},[7184],{"nctId":7185,"briefTitle":7186,"status":153,"phases":7187,"primaryCompletion":832,"completion":832,"start":7188,"enrollment":7189,"conditions":7190,"interventions":7192},"NCT00567606","Prevention of Osteoporosis in Breast Cancer Survivors",[92],"2002-04-01",249,[7191],"Postmenopausal Osteoporosis",[7170],{"intervention":7194,"totalTrials":95,"cells":7195},"Omnipaque 240 Contrast Solution",{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7206},{"trials":7197,"activeCount":99},[],{"trials":7199,"activeCount":99},[],{"trials":7201,"activeCount":99},[],{"trials":7203,"activeCount":99},[],{"trials":7205,"activeCount":99},[],{"trials":7207,"activeCount":99},[7208],{"nctId":7209,"briefTitle":7210,"status":153,"phases":7211,"primaryCompletion":7212,"completion":7212,"start":7213,"enrollment":7214,"conditions":7215,"interventions":7217},"NCT00626366","Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison",[92],"2009-01-09","2008-03-12",18,[7216],"Chronic Sinusitis",[7194,7218],"Omnipaque 240 mg I\u002FmL",{"intervention":7218,"totalTrials":95,"cells":7220},{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7225,"PHASE3":7227,"PHASE4":7229,"NA":7231},{"trials":7222,"activeCount":99},[],{"trials":7224,"activeCount":99},[],{"trials":7226,"activeCount":99},[],{"trials":7228,"activeCount":99},[],{"trials":7230,"activeCount":99},[],{"trials":7232,"activeCount":99},[7233],{"nctId":7209,"briefTitle":7210,"status":153,"phases":7234,"primaryCompletion":7212,"completion":7212,"start":7213,"enrollment":7214,"conditions":7235,"interventions":7236},[92],[7216],[7194,7218]]